

Reference Section A
incidence of reported esrd



table a.1 · 263

incident counts of reported esrd: all patients
by demographic characteristics & primary diagnosis

table a.2 · 264

incident counts of reported esrd patients: u.s. only, with unknowns dropped
by demographic characteristics & primary diagnosis, after dropping non-u.s. patients & patients of unknown age, gender, or race

table a.3 · 265

incident rates of reported esrd, unadjusted
per million population, by demographic characteristics & primary diagnosis

table a.4 · 266

incident rates of reported esrd, Adjusted
per million population, by demographic characteristics & primary diagnosis, adjusted for age, gender, race, & ethnicity

table a.5 · 267

incident counts of reported esrd patients: by time period

table a.6 · 268

incident rates of reported esrd: by time period
per million population, adjusted for & grouped by age, gender, & race

table a.7 · 269

incident counts of reported esrd patients: by primary diagnosis
1997-2000 combined, by age; grouped by gender & race

table a.8 · 273

incident rates of reported esrd: by primary diagnosis
per ten million population, 1997-2000 combined, adjusted for & grouped by age, gender, & race

table a.9 · 276

mean age at start of esrd therapy
by demographic characteristics & primary diagnosis

table a.10 · 277

incidence of reported esrd, by primary diagnosis: all patients, row percent
1996-2000 combined, by detailed primary diagnosis

table a.11 · 278

incidence of reported esrd, by primary diagnosis: all patients, column percent
1996-2000 combined, by detailed primary diagnosis

table a.12 · 279

incidence of reported esrd, by primary diagnosis: hispanics, row percent
1996-2000 combined, by detailed primary diagnosis

table a.13 · 280

incidence of reported esrd, by primary diagnosis: hispanics, column percent
1996-2000 combined, by detailed primary diagnosis

table a.14 · 281

incidence of reported esrd, by primary diagnosis: non-hispanics, row percent
1996-2000 combined, by detailed primary diagnosis

table a.15 · 282

incidence of reported esrd, by primary diagnosis: non-hispanics, column percent
1996-2000 combined, by detailed primary diagnosis

table a.16 · 283

incident counts of reported esrd patients, by diabetic status & state/territory: all patients

table a.17 · 286

incident counts of reported esrd patients, by diabetic status & state: u.s. only with unknowns dropped

table a.18 · 289

incident rates of reported esrd, by diabetic status & state
per million population, adjusted for age, gender, & race

table a.19 · 292

incident counts of reported esrd patients, by diabetic status & esrd network: all patients

table a.20 · 293

incident counts of reported esrd patients: u.s. only, with unknowns dropped

table a.21 · 294

incident rates of reported esrd, by diabetic status & esrd network
per million population, adjusted for age, gender, & race

Table A.1
Incident Counts of Reported ESRD: All Patients
by demographic characteristics & primary diagnosis

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	167	148	172	165	184	204	202	193	209	254
5-9	143	122	144	172	157	154	142	142	176	163
10-14	250	245	248	272	295	289	294	285	310	321
15-19	474	503	525	582	585	604	558	549	615	620
20-24	935	1,019	984	1,124	1,080	1,059	978	1,038	982	1,075
25-29	1,585	1,598	1,666	1,958	1,703	1,713	1,724	1,762	1,709	1,844
30-34	2,176	2,246	2,337	2,796	2,596	2,504	2,445	2,523	2,508	2,647
35-39	2,623	2,891	2,855	3,682	3,420	3,413	3,392	3,426	3,527	3,534
40-44	3,230	3,425	3,428	4,159	4,221	4,386	4,308	4,667	4,670	4,967
45-49	3,374	3,706	3,999	5,036	5,095	5,419	5,469	5,926	6,183	6,546
50-54	3,679	4,233	4,442	5,791	5,683	5,853	6,423	7,046	7,681	8,176
55-59	4,734	5,163	5,324	6,768	6,672	6,915	7,430	8,095	8,651	9,224
60-64	6,339	6,674	6,906	8,219	8,352	8,543	8,975	9,548	9,754	10,277
65-69	7,952	8,576	8,886	9,942	9,651	10,276	10,755	11,004	11,135	11,452
70-74	7,250	8,089	8,521	9,739	9,659	10,629	11,206	11,582	11,923	12,292
75-79	5,355	5,983	6,285	7,299	7,395	8,403	9,285	10,068	11,080	11,497
80-84	2,743	3,219	3,418	4,076	4,281	4,931	5,716	6,084	6,739	7,384
85+	1,104	1,273	1,479	1,671	1,838	2,232	2,603	3,116	3,560	3,887
Unknown	*	14	*	29	*	*	*	*	12	32
0-19	1,034	1,018	1,089	1,191	1,221	1,251	1,196	1,169	1,310	1,358
20-44	10,549	11,179	11,270	13,719	13,020	13,075	12,847	13,416	13,396	14,067
45-64	18,126	19,776	20,671	25,814	25,802	26,730	28,297	30,615	32,269	34,223
65-74	15,202	16,665	17,407	19,681	19,310	20,905	21,961	22,586	23,058	23,744
75+	9,202	10,475	11,182	13,046	13,514	15,566	17,604	19,268	21,379	22,768
Unknown	*	14	*	29	*	*	*	*	12	32
Male	29,055	31,361	32,866	38,516	38,417	41,415	43,556	46,299	48,886	51,573
Female	25,061	27,760	28,751	34,901	34,439	36,094	38,350	40,757	42,531	44,611
Unknown	*	*	10	63	18	22	*	*	*	*
White	35,282	38,115	38,815	44,739	44,635	47,281	51,878	54,703	58,508	61,548
Black	16,245	17,840	19,012	22,239	22,759	24,157	24,473	26,173	26,764	27,540
Native American	732	877	836	1,010	1,188	1,348	985	1,423	1,144	1,222
Asian	1,392	1,592	1,854	2,367	2,540	2,760	2,701	3,089	3,229	3,284
Other/unknown	471	703	1,110	3,125	1,752	1,985	1,874	1,674	1,779	2,598
†Hispanic					7,182	8,963	9,080	10,029	10,367	11,266
†Non-Hispanic					65,692	68,568	72,831	77,033	81,057	84,926
Diabetes	19,222	21,390	21,379	26,123	29,062	32,661	35,358	37,831	39,718	41,772
Hypertension	15,824	17,722	16,985	20,460	18,397	19,731	21,359	22,659	23,871	24,566
Glomerulonephritis	6,310	6,592	6,504	7,482	7,720	8,235	8,219	8,391	8,316	8,102
Cystic kidney	1,534	1,630	1,584	1,799	1,892	1,877	1,966	2,138	2,162	2,144
Other urologic	1,136	1,176	1,054	1,181	1,343	1,560	1,499	1,557	1,668	1,630
Other cause	5,061	5,382	5,341	6,503	8,064	8,575	8,962	9,544	10,004	10,444
Unknown cause	2,308	2,567	2,292	2,583	2,602	2,996	3,159	3,433	3,486	3,841
Missing disease	2,727	2,668	6,488	7,349	3,794	1,896	1,389	1,509	2,199	3,693
U.S.	52,817	57,443	59,540	67,461	71,464	76,332	80,717	85,779	90,055	94,778
U.S. territories	61	86	66	77	105	121	143	142	138	145
Puerto Rico	628	725	685	857	854	954	971	1,048	1,114	1,106
Foreign	46	53	54	67	40	44	44	50	30	37
Unknown	570	820	1,282	5,018	411	80	36	43	87	126
All	54,122	59,127	61,627	73,480	72,874	77,531	81,911	87,062	91,424	96,192

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

*Values for cells with fewer than 10 patients are suppressed.

Table A.2

Incident Counts of Reported ESRD Patients: U.S. Only, With Unknowns Dropped

by demographic characteristics & primary diagnosis, after dropping non-U.S. patients & patients of unknown age, race, or gender

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	156	139	160	127	162	181	179	168	195	232
5-9	129	111	128	150	150	142	133	125	157	151
10-14	238	224	231	239	275	271	271	272	295	296
15-19	455	470	480	507	551	566	524	520	589	552
20-24	878	957	916	944	1,014	999	910	982	928	971
25-29	1,505	1,519	1,542	1,634	1,612	1,615	1,634	1,673	1,628	1,712
30-34	2,093	2,152	2,206	2,350	2,455	2,392	2,341	2,399	2,386	2,492
35-39	2,537	2,782	2,701	3,097	3,255	3,279	3,274	3,300	3,393	3,377
40-44	3,105	3,264	3,234	3,519	4,031	4,195	4,171	4,508	4,515	4,709
45-49	3,231	3,548	3,798	4,378	4,858	5,160	5,251	5,745	5,981	6,247
50-54	3,538	4,035	4,192	5,039	5,391	5,610	6,119	6,767	7,379	7,803
55-59	4,537	4,932	5,017	5,957	6,343	6,593	7,112	7,788	8,303	8,783
60-64	6,185	6,455	6,612	7,452	8,020	8,186	8,624	9,199	9,404	9,826
65-69	7,811	8,366	8,661	9,458	9,314	9,967	10,412	10,711	10,812	11,105
70-74	7,129	7,923	8,346	9,342	9,453	10,374	10,957	11,320	11,684	11,981
75-79	5,302	5,893	6,160	7,058	7,240	8,215	9,104	9,900	10,877	11,285
80-84	2,716	3,193	3,356	3,925	4,196	4,843	5,630	6,026	6,626	7,276
85+	1,088	1,251	1,449	1,588	1,798	2,187	2,554	3,081	3,502	3,837
0-19	978	944	999	1,023	1,138	1,160	1,107	1,085	1,236	1,231
20-44	10,118	10,674	10,599	11,544	12,367	12,480	12,330	12,862	12,850	13,261
45-64	17,491	18,970	19,619	22,826	24,612	25,549	27,106	29,499	31,067	32,659
65-74	14,940	16,289	17,007	18,800	18,767	20,341	21,369	22,031	22,496	23,086
75+	9,106	10,337	10,965	12,571	13,234	15,245	17,288	19,007	21,005	22,398
Male	28,266	30,424	31,656	35,395	36,963	39,927	42,078	44,827	47,304	49,526
Female	24,367	26,790	27,533	31,369	33,155	34,848	37,122	39,657	41,350	43,109
White	34,514	37,261	37,892	42,410	43,980	46,746	51,258	54,038	57,780	60,816
Black	16,058	17,569	18,689	21,195	22,510	24,017	24,362	26,045	26,611	27,430
Native American	725	870	829	965	1,184	1,348	984	1,421	1,142	1,220
Asian	1,336	1,514	1,779	2,194	2,444	2,664	2,596	2,980	3,121	3,169
†Hispanic					5,587	7,025	7,042	8,157	8,384	8,960
†Non-Hispanic					64,531	67,750	72,158	76,327	80,270	83,675
Diabetes	18,732	20,724	20,676	24,684	27,893	31,333	33,994	36,578	38,339	40,142
Hypertension	15,645	17,423	16,612	19,570	17,943	19,311	20,896	22,229	23,464	24,071
Glomerulonephritis	6,158	6,433	6,305	7,070	7,438	7,950	7,914	8,101	8,047	7,748
Cystic kidney	1,508	1,601	1,545	1,703	1,844	1,814	1,916	2,083	2,116	2,067
Other urologic	1,112	1,151	1,024	1,114	1,298	1,510	1,444	1,518	1,604	1,571
Other cause	4,969	5,261	5,186	6,093	7,817	8,351	8,758	9,324	9,783	10,154
Unknown cause	2,259	2,500	2,212	2,404	2,501	2,879	3,057	3,325	3,380	3,687
Missing disease	2,250	2,121	5,629	4,126	3,384	1,627	1,221	1,326	1,921	3,195
All	52,633	57,214	59,189	66,764	70,118	74,775	79,200	84,484	88,654	92,635
Patients dropped	1,489	1,913	2,438	6,716	2,756	2,756	2,711	2,578	2,770	3,557

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table A.3

Incident Rates of Reported ESRD, Unadjusted*per million population, by demographic characteristics & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	8	7	8	6	8	9	9	9	10	12
5-9	7	6	7	8	8	7	7	6	8	8
10-14	13	12	12	13	15	14	14	14	15	15
15-19	26	27	28	29	30	30	27	27	30	28
20-24	46	50	49	51	56	57	52	56	51	53
25-29	73	75	79	86	85	85	87	90	89	96
30-34	94	97	99	106	112	112	113	119	121	127
35-39	124	132	125	141	146	145	145	146	151	152
40-44	166	174	168	178	199	202	195	206	203	208
45-49	229	231	238	262	278	280	284	305	309	314
50-54	304	335	329	382	395	403	404	430	449	452
55-59	435	470	470	545	572	581	605	628	645	660
60-64	585	618	646	740	798	819	857	896	894	922
65-69	779	839	865	949	938	1,007	1,065	1,117	1,144	1,178
70-74	865	936	969	1,069	1,070	1,180	1,252	1,287	1,332	1,370
75-79	844	921	950	1,072	1,081	1,192	1,285	1,372	1,484	1,523
80-84	672	771	789	900	937	1,059	1,208	1,274	1,375	1,484
85+	341	377	420	446	488	575	653	761	839	893
0-19	14	13	14	14	15	15	14	14	16	16
20-44	100	105	105	114	122	123	122	127	128	132
45-64	374	392	396	449	471	476	489	515	525	534
65-74	818	883	913	1,005	1,001	1,088	1,153	1,198	1,235	1,271
75+	674	746	773	867	890	999	1,104	1,188	1,287	1,349
Male	230	245	252	279	288	308	322	340	355	368
Female	189	205	209	235	246	257	271	287	297	307
White	164	175	176	196	202	213	232	242	257	269
Black	516	555	580	649	680	716	717	757	763	777
Native American	343	405	379	434	525	589	423	602	476	501
Asian	168	182	204	242	260	273	256	284	288	281
†Hispanic					206	250	241	270	268	276
†Non-Hispanic					274	286	302	318	333	345
Diabetes	74	81	80	95	106	118	127	135	141	146
Hypertension	62	68	64	75	68	73	78	82	86	87
Glomerulonephritis	24	25	24	27	28	30	30	30	30	28
Cystic kidney	6	6	6	7	7	7	7	8	8	8
Other urologic	4	5	4	4	5	6	5	6	6	6
Other cause	20	21	20	23	30	31	33	35	36	37
Unknown cause	9	10	9	9	10	11	11	12	12	13
Missing disease	9	8	22	16	13	6	5	5	7	12
All	209	224	230	256	267	282	296	313	325	337

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table A.4

Incident Rates of Reported ESRD, Adjusted

per million population, by demographic characteristics & primary diagnosis, adjusted for age, gender, race, & ethnicity

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	8	7	8	6	8	9	9	9	10	12
5-9	7	6	7	8	8	7	7	6	8	8
10-14	13	12	12	12	14	14	14	14	15	14
15-19	25	26	26	27	29	29	26	25	29	27
20-24	45	49	47	49	53	54	49	53	49	50
25-29	72	74	77	83	83	83	84	87	86	92
30-34	95	97	99	106	112	111	111	117	118	125
35-39	126	134	127	143	147	146	145	146	150	150
40-44	175	181	175	186	206	208	200	210	205	210
45-49	248	252	260	285	301	300	300	319	322	325
50-54	328	362	359	418	434	442	443	470	487	486
55-59	477	514	514	596	622	634	653	687	703	718
60-64	649	688	715	810	876	893	929	974	966	987
65-69	880	941	978	1,055	1,035	1,111	1,157	1,209	1,231	1,262
70-74	985	1,066	1,120	1,222	1,229	1,348	1,410	1,451	1,477	1,506
75-79	994	1,080	1,114	1,263	1,269	1,408	1,472	1,582	1,689	1,718
80-84	848	961	988	1,104	1,149	1,316	1,453	1,536	1,641	1,763
85+	490	525	566	608	657	805	860	1,005	1,092	1,147
0-19	13	13	13	13	15	15	14	13	15	15
20-44	102	107	105	113	120	120	118	122	122	125
45-64	426	454	462	527	558	567	581	613	620	629
65-74	933	1,003	1,049	1,139	1,132	1,229	1,284	1,330	1,354	1,384
75+	777	855	889	992	1,025	1,176	1,262	1,374	1,474	1,543
Male	266	282	289	318	326	348	361	378	393	403
Female	182	197	200	224	235	243	254	267	274	281
White	161	171	172	190	195	205	222	231	244	254
Black	694	745	779	862	891	942	938	984	984	995
Native American	548	654	605	664	790	880	626	889	687	716
Asian	252	270	299	352	384	400	369	405	406	393
†Hispanic					351	425	408	454	446	454
†Non-Hispanic					268	278	292	305	317	327
Diabetes	78	85	83	98	109	121	129	137	141	145
Hypertension	66	72	68	78	71	75	79	83	86	87
Glomerulonephritis	26	26	25	28	29	31	30	30	30	28
Cystic kidney	6	7	6	7	7	7	7	8	8	7
Other urologic	5	5	4	4	5	6	5	6	6	6
Other cause	20	21	21	24	30	32	33	35	36	37
Unknown cause	9	10	9	10	10	11	12	12	12	13
Missing disease	9	9	23	17	13	6	5	5	7	11
All (crude)	209	224	230	256	267	282	296	313	325	337
All (adjusted)	219	235	239	266	275	289	300	315	325	334

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table A.5

Incident Counts of Reported ESRD Patients: by Time Period

1995-1997	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	226	70	*	13	312	143	55	*	*	210	369	125	*	21	522
5-9	171	64	*	*	246	136	35	*	*	179	307	99	*	13	425
10-14	292	140	*	14	451	229	106	*	23	366	521	246	13	37	817
15-19	550	344	10	33	937	417	238	11	38	704	967	582	21	71	1,641
20-29	2,213	1,837	48	155	4,253	1,777	1,537	67	150	3,531	3,990	3,374	115	305	7,784
30-39	5,237	4,414	157	282	10,090	3,417	3,076	121	292	6,906	8,654	7,490	278	574	16,996
40-49	8,485	6,966	332	459	16,242	5,849	4,872	265	438	11,424	14,334	11,838	597	897	27,666
50-59	11,810	6,883	419	711	19,823	9,361	6,923	486	575	17,345	21,171	13,806	905	1,286	37,168
60-64	8,150	3,648	185	434	12,417	7,073	4,657	262	421	12,413	15,223	8,305	447	855	24,830
65-69	10,753	3,356	170	505	14,784	9,216	4,860	285	548	14,909	19,969	8,216	455	1,053	29,693
70-79	22,663	4,945	204	905	28,717	17,807	7,514	342	963	26,626	40,470	12,459	546	1,868	55,343
80+	8,701	1,583	40	372	10,696	7,308	2,766	86	352	10,512	16,009	4,349	126	724	21,208
0-19	1,239	618	21	68	1,946	925	434	26	74	1,459	2,164	1,052	47	142	3,405
20-44	11,297	9,523	344	629	21,793	7,631	6,831	284	638	15,384	18,928	16,354	628	1,267	37,177
45-64	24,598	14,225	797	1,412	41,032	19,846	14,234	917	1,238	36,235	44,444	28,459	1,714	2,650	77,267
65-74	23,051	6,231	290	985	30,557	19,024	9,302	506	1,088	29,920	42,075	15,533	796	2,073	60,477
75+	19,066	3,653	124	797	23,640	15,307	5,838	207	775	22,127	34,373	9,491	331	1,572	45,767
All	79,251	34,250	1,576	3,891	118,968	62,733	36,639	1,940	3,813	105,125	141,984	70,889	3,516	7,704	224,093
1998-2000															
0-4	269	83	*	*	360	180	45	*	*	235	449	128	*	14	595
5-9	180	49	*	*	238	139	50	*	*	195	319	99	*	*	433
10-14	318	116	12	14	460	269	113	*	18	403	587	229	15	32	863
15-19	531	282	*	36	857	474	281	10	39	804	1,005	563	18	75	1,661
20-29	2,337	1,716	42	202	4,297	1,811	1,547	54	185	3,597	4,148	3,263	96	387	7,894
30-39	5,421	4,232	127	330	10,110	3,609	3,225	106	297	7,237	9,030	7,457	233	627	17,347
40-49	9,949	7,683	325	584	18,541	6,762	5,640	286	476	13,164	16,711	13,323	611	1,060	31,705
50-59	15,339	8,750	536	882	25,507	12,035	8,047	507	727	21,316	27,374	16,797	1,043	1,609	46,823
60-64	9,588	4,073	246	502	14,409	8,206	5,029	303	482	14,020	17,794	9,102	549	984	28,429
65-69	11,939	3,859	176	555	16,529	9,999	5,256	264	580	16,099	21,938	9,115	440	1,135	32,628
70-79	27,530	5,789	252	1,162	34,733	22,205	8,592	364	1,153	32,314	49,735	14,381	616	2,315	67,047
80+	13,007	2,048	62	499	15,616	10,537	3,581	88	526	14,732	23,544	5,629	150	1,025	30,348
0-19	1,298	530	26	61	1,915	1,062	489	19	67	1,637	2,360	1,019	45	128	3,552
20-44	12,020	9,377	299	788	22,484	8,303	7,258	256	672	16,489	20,323	16,635	555	1,460	38,973
45-64	30,614	17,077	977	1,712	50,380	24,120	16,230	1,000	1,495	42,845	54,734	33,307	1,977	3,207	93,225
65-74	25,801	7,123	336	1,161	34,421	21,440	10,069	475	1,208	33,192	47,241	17,192	811	2,369	67,613
75+	26,675	4,573	154	1,055	32,457	21,301	7,360	241	1,051	29,953	47,976	11,933	395	2,106	62,410
All	96,408	38,680	1,792	4,777	141,657	76,226	41,406	1,991	4,493	124,116	172,634	80,086	3,783	9,270	265,773

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

*Values for cells with fewer than 10 patients are suppressed.

Table A.6
Incident Rates of Reported ESRD: by Time Period
per million population, adjusted for & grouped by age, gender, & race

1995-1997	Rates (unadjusted)				Female				Rates (adjusted)				Race		Gender &
	Male				White				Gender				Male	Female	Race
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian			
0-4	10	16	*	10	6	13	*	*	8	14	*	8	10	7	9
5-9	7	14	*	*	6	8	*	*	7	11	*	6	8	6	7
10-14	13	32	*	12	10	25	*	20	11	28	18	16	15	13	14
15-19	24	78	31	30	19	55	35	36	22	66	34	33	31	25	28
20-29	50	241	83	66	41	190	123	60	45	215	104	62	75	61	68
30-39	96	557	286	112	64	343	219	105	79	447	253	109	157	102	129
40-49	174	1,128	781	223	119	676	589	187	147	917	708	210	308	200	252
50-59	366	1,987	1,689	599	277	1,594	1,792	435	327	1,815	1,798	530	605	475	538
60-64	656	2,847	2,225	1,100	519	2,727	2,760	866	586	2,786	2,502	982	968	834	900
65-69	902	2,816	2,612	1,632	658	3,042	3,652	1,275	778	2,931	3,148	1,449	1,191	1,013	1,101
70-79	1,259	3,368	2,386	2,236	736	3,367	3,074	1,773	996	3,356	2,725	2,057	1,589	1,131	1,356
80+	1,161	2,738	1,106	2,335	477	2,219	1,333	1,677	780	2,425	1,224	1,924	1,348	745	1,040
0-19	13	34	16	14	10	25	20	16	12	30	18	16	16	13	14
20-44	90	501	253	105	62	325	211	97	74	414	240	101	144	97	119
45-64	364	1,909	1,528	564	281	1,535	1,617	431	354	1,876	1,757	575	635	507	569
65-74	1,037	3,036	2,480	1,774	698	3,257	3,559	1,434	869	3,184	3,020	1,621	1,349	1,085	1,215
75+	1,256	3,081	1,776	2,503	582	2,630	1,855	1,829	864	2,708	1,669	2,057	1,456	865	1,154
All	245	717	463	275	187	693	559	251	215	704	512	263	306	258	282
All (age adjusted)	259	1,012	720	438	168	843	801	343	207	924	766	384	345	244	288
1998-2000															
0-4	12	19	*	*	8	11	*	*	10	15	*	5	12	8	10
5-9	7	10	*	*	6	11	*	*	7	11	*	*	8	7	7
10-14	13	25	32	11	12	25	*	15	13	25	20	13	15	14	14
15-19	22	61	*	29	21	63	29	32	21	62	26	31	27	27	27
20-29	53	221	71	83	42	189	94	71	48	206	84	76	76	63	69
30-39	105	538	228	120	70	364	195	98	87	447	211	109	161	110	134
40-49	192	1,108	702	247	130	704	589	180	162	922	668	217	322	213	265
50-59	416	2,202	1,905	613	312	1,617	1,646	443	372	1,946	1,828	552	680	509	592
60-64	741	3,013	2,730	1,073	581	2,773	2,935	886	659	2,892	2,842	979	1,062	894	976
65-69	1,044	3,211	2,589	1,586	755	3,260	3,193	1,239	896	3,236	2,901	1,408	1,356	1,116	1,234
70-79	1,479	3,681	2,653	2,492	909	3,694	3,015	1,772	1,197	3,702	2,814	2,161	1,830	1,321	1,571
80+	1,567	3,285	1,455	2,587	652	2,735	1,160	1,946	1,074	2,967	1,310	2,219	1,773	971	1,364
0-19	14	29	19	12	12	27	14	13	13	28	16	13	16	14	15
20-44	97	481	213	122	68	339	185	95	79	406	205	107	145	102	123
45-64	414	2,033	1,684	574	313	1,556	1,581	438	399	1,976	1,849	588	703	543	621
65-74	1,184	3,357	2,744	1,874	818	3,448	3,173	1,421	1,001	3,426	2,976	1,673	1,514	1,203	1,356
75+	1,610	3,583	1,854	2,706	771	3,163	1,861	1,952	1,145	3,241	1,732	2,274	1,845	1,098	1,464
All	291	779	503	305	222	754	548	266	256	766	526	285	354	297	325
All (age adjusted)	304	1,083	765	467	197	902	760	351	243	988	764	401	391	274	325

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 The age of the incident patient is determined as of the date of ESRD initiation.
 U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.
 *Values for cells with fewer than 10 patients are suppressed.

Table A.7
Incident Counts of Reported ESRD Patients: by Primary Diagnosis
 1997-2000 combined, by age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	11	*	.	.	18	14	10	*	.	25	25	17	*	.	43
5-9	.	*	.	.	*	*	*	.	.	*	*	*	.	.	*
10-14	*	*	.	.	*	.	*	.	.	*	*	*	.	.	*
15-19	*	*	.	.	14	15	10	.	.	25	24	15	.	.	39
20-29	554	273	13	*	848	596	370	19	20	1,005	1,150	643	32	28	1,853
30-39	3,010	934	79	73	4,096	1,956	887	68	58	2,969	4,966	1,821	147	131	7,065
40-49	5,965	2,763	266	267	9,261	4,020	2,669	253	184	7,126	9,985	5,432	519	451	16,387
50-59	10,530	5,059	513	613	16,715	8,804	6,003	542	477	15,826	19,334	11,062	1,055	1,090	32,541
60-64	6,478	2,719	223	371	9,791	6,470	4,072	338	414	11,294	12,948	6,791	561	785	21,085
65-69	7,407	2,556	149	409	10,521	7,571	4,224	292	485	12,572	14,978	6,780	441	894	23,093
70-79	12,863	3,160	192	697	16,912	13,136	5,899	326	835	20,196	25,999	9,059	518	1,532	37,108
80+	3,399	732	38	200	4,369	3,494	1,632	66	270	5,462	6,893	2,364	104	470	9,831
0-19	21	15	.	.	36	30	23	*	.	54	51	38	*	.	90
20-44	6,020	2,224	193	175	8,612	4,192	2,232	166	134	6,724	10,212	4,456	359	309	15,336
45-64	20,517	9,524	901	1,157	32,099	17,654	11,769	1,054	1,019	31,496	38,171	21,293	1,955	2,176	63,595
65-74	14,666	4,485	279	790	20,220	15,073	7,776	498	965	24,312	29,739	12,261	777	1,755	44,532
75+	9,003	1,963	100	516	11,582	9,128	3,979	186	625	13,918	18,131	5,942	286	1,141	25,500
All	50,227	18,211	1,473	2,638	72,549	46,077	25,779	1,905	2,743	76,504	96,304	43,990	3,378	5,381	149,053
HYPERTENSION															
0-4	*	*	.	.	16	11	*	*	.	20	20	15	*	.	36
5-9	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
10-14	*	*	.	.	*	*	*	*	*	10	11	*	*	*	18
15-19	21	74	.	.	95	24	45	.	*	70	45	119	.	*	165
20-29	324	765	*	53	1,147	144	404	*	22	575	468	1,169	10	75	1,722
30-39	693	2,033	19	88	2,833	352	1,180	10	57	1,599	1,045	3,213	29	145	4,432
40-49	1,398	3,800	38	143	5,379	744	2,201	25	117	3,087	2,142	6,001	63	260	8,466
50-59	2,529	3,573	58	195	6,355	1,608	2,598	20	166	4,392	4,137	6,171	78	361	10,747
60-64	2,320	1,662	25	135	4,142	1,522	1,673	19	103	3,317	3,842	3,335	44	238	7,459
65-69	3,942	1,677	31	158	5,808	2,564	1,918	26	161	4,669	6,506	3,595	57	319	10,477
70-79	12,451	2,972	59	493	15,975	8,584	4,035	75	377	13,071	21,035	7,007	134	870	29,046
80+	7,668	1,320	20	288	9,296	6,170	2,323	28	266	8,787	13,838	3,643	48	554	18,083
0-19	40	85	.	.	125	41	58	*	*	103	81	143	*	*	228
20-44	1,636	4,564	39	209	6,448	807	2,590	27	126	3,550	2,443	7,154	66	335	9,998
45-64	5,628	7,269	106	405	13,408	3,563	5,466	52	339	9,420	9,191	12,735	158	744	22,828
65-74	9,735	3,234	62	394	13,425	6,479	4,016	67	348	10,910	16,214	7,250	129	742	24,335
75+	14,326	2,735	48	545	17,654	10,839	4,260	62	456	15,617	25,165	6,995	110	1,001	33,271
All	31,365	17,887	255	1,553	51,060	21,729	16,390	210	1,271	39,600	53,094	34,277	465	2,824	90,660

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.7 (continued)
Incident Counts of Reported ESRD Patients: by Primary Diagnosis
 1997-2000 combined, by age; grouped by gender & race

GLOMERU- LONEPHRITIS	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	24	*	.	*	36	21	*	.	*	26	45	10	.	*	62
5-9	50	13	*	*	66	47	20	*	*	72	97	33	*	*	138
10-14	87	40	*	*	139	84	57	*	*	149	171	97	*	11	288
15-19	245	161	*	27	437	183	125	*	21	333	428	286	*	48	770
20-29	1,001	584	24	128	1,737	592	436	25	88	1,141	1,593	1,020	49	216	2,878
30-39	1,473	908	34	179	2,594	769	655	26	148	1,598	2,242	1,563	60	327	4,192
40-49	1,947	1,151	53	160	3,311	1,002	715	28	179	1,924	2,949	1,866	81	339	5,235
50-59	2,069	810	36	152	3,067	1,204	495	29	109	1,837	3,273	1,305	65	261	4,904
60-64	1,106	265	16	62	1,449	588	218	10	49	865	1,694	483	26	111	2,314
65-69	1,302	250	14	68	1,634	796	224	11	59	1,090	2,098	474	25	127	2,724
70-79	3,024	314	19	135	3,492	1,770	344	20	113	2,247	4,794	658	39	248	5,739
80+	1,322	100	*	58	1,483	886	143	*	48	1,083	2,208	243	*	106	2,566
0-19	406	223	12	37	678	335	203	*	34	580	741	426	20	71	1,258
20-44	3,372	2,054	81	400	5,907	1,831	1,434	65	316	3,646	5,203	3,488	146	716	9,553
45-64	4,224	1,664	82	281	6,251	2,324	1,085	53	257	3,719	6,548	2,749	135	538	9,970
65-74	2,878	442	26	139	3,485	1,679	423	22	128	2,252	4,557	865	48	267	5,737
75+	2,770	222	10	122	3,124	1,773	288	15	92	2,168	4,543	510	25	214	5,292
All	13,650	4,605	211	979	19,445	7,942	3,433	163	827	12,365	21,592	8,038	374	1,806	31,810
CYSTIC KIDNEY															
0-4	22	*	.	*	27	29	*	.	*	32	51	*	.	*	59
5-9	*	*	*	.	11	15	*	.	.	17	23	*	*	.	28
10-14	21	*	.	*	24	24	*	*	.	26	45	*	*	*	50
15-19	16	*	.	.	18	21	*	.	*	27	37	*	.	*	45
20-29	40	*	.	*	52	50	*	.	*	57	90	13	.	*	109
30-39	314	43	*	10	369	194	50	.	*	246	508	93	*	12	615
40-49	1,026	141	*	34	1,206	745	165	*	13	929	1,771	306	11	47	2,135
50-59	1,050	134	*	25	1,216	952	147	*	25	1,125	2,002	281	*	50	2,341
60-64	305	49	*	10	366	319	52	*	14	387	624	101	*	24	753
65-69	282	43	.	10	335	287	36	*	*	330	569	79	*	16	665
70-79	443	74	*	14	534	436	66	*	14	517	879	140	*	28	1,051
80+	153	32	.	*	187	128	14	*	*	144	281	46	*	*	331
0-19	67	10	*	*	80	89	*	*	*	102	156	19	*	*	182
20-44	807	115	*	26	953	531	126	*	*	668	1,338	241	*	35	1,621
45-64	1,928	261	11	56	2,256	1,729	292	*	48	2,076	3,657	553	18	104	4,332
65-74	519	84	*	19	623	530	73	*	16	621	1,049	157	*	35	1,244
75+	359	65	*	*	433	321	43	*	*	370	680	108	*	12	803
All	3,680	535	20	110	4,345	3,200	543	13	81	3,837	6,880	1,078	33	191	8,182

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 The age of the incident patient is determined as of the date of ESRD initiation.
 U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.
 *Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table A.7 (continued)

Incident Counts of Reported ESRD Patients: by Primary Diagnosis

1997-2000 combined, by age; grouped by gender & race

OTHER UROLOGIC	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	*	*	.	.	*	*	10
5-9	*	*	.	.	12	14	*	.	.	17	23	*	.	.	29
10-14	29	*	.	*	34	29	*	.	*	35	58	*	.	*	69
15-19	37	*	.	*	47	53	*	.	.	61	90	16	.	*	108
20-29	115	17	*	*	138	157	15	*	*	177	272	32	*	*	315
30-39	172	48	*	*	229	213	16	*	*	234	385	64	*	10	463
40-49	218	52	*	*	279	252	47	*	*	306	470	99	*	14	585
50-59	325	86	*	10	425	282	69	*	16	373	607	155	10	26	798
60-64	290	47	*	*	349	153	27	*	*	187	443	74	*	14	536
65-69	342	77	*	12	433	182	49	*	*	239	524	126	*	19	672
70-79	986	152	*	19	1,163	395	53	*	17	468	1,381	205	*	36	1,631
80+	605	70	*	12	688	183	43	.	*	233	788	113	*	19	921
0-19	81	16	.	*	100	98	17	.	*	116	179	33	.	*	216
20-44	399	89	*	13	506	493	56	*	10	563	892	145	*	23	1,069
45-64	721	161	*	24	914	564	118	*	23	714	1,285	279	17	47	1,628
65-74	786	152	*	23	967	391	83	*	17	494	1,177	235	*	40	1,461
75+	1,147	147	*	20	1,317	369	62	*	14	446	1,516	209	*	34	1,763
All	3,134	565	22	83	3,804	1,915	336	17	65	2,333	5,049	901	39	148	6,137
OTHER CAUSE															
0-4	233	70	*	*	310	120	37	*	*	165	353	107	*	11	475
5-9	113	34	*	*	153	80	26	*	*	109	193	60	*	*	262
10-14	201	63	*	*	277	142	66	*	12	222	343	129	*	20	499
15-19	251	86	*	*	350	219	120	*	23	368	470	206	11	31	718
20-29	634	409	*	37	1,087	591	664	14	64	1,333	1,225	1,073	21	101	2,420
30-39	870	1,181	20	30	2,101	853	1,155	16	72	2,096	1,723	2,336	36	102	4,197
40-49	1,387	1,468	27	38	2,920	1,283	1,075	25	54	2,437	2,670	2,543	52	92	5,357
50-59	1,987	852	28	50	2,917	1,785	648	32	49	2,514	3,772	1,500	60	99	5,431
60-64	1,306	311	18	24	1,659	1,066	308	*	20	1,400	2,372	619	24	44	3,059
65-69	1,766	279	*	41	2,095	1,283	279	15	34	1,611	3,049	558	24	75	3,706
70-79	4,024	487	15	76	4,602	3,003	477	18	62	3,560	7,027	964	33	138	8,162
80+	1,852	172	*	33	2,063	1,424	216	*	26	1,670	3,276	388	10	59	3,733
0-19	798	253	15	24	1,090	561	249	12	42	864	1,359	502	27	66	1,954
20-44	2,120	2,356	37	83	4,596	2,026	2,392	42	167	4,627	4,146	4,748	79	250	9,223
45-64	4,064	1,865	63	96	6,088	3,552	1,458	51	92	5,153	7,616	3,323	114	188	11,241
65-74	3,779	568	20	79	4,446	2,798	533	25	68	3,424	6,577	1,101	45	147	7,870
75+	3,863	370	10	71	4,314	2,912	439	12	54	3,417	6,775	809	22	125	7,731
All	14,624	5,412	145	353	20,534	11,849	5,071	142	423	17,485	26,473	10,483	287	776	38,019

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.7 (continued)
Incident Counts of Reported ESRD Patients: by Primary Diagnosis
 1997-2000 combined, by age; grouped by gender & race

UNKNOWN CAUSE	Male					Female					All					
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	
0-4	10	*	.	*	14	*	*	.	*	*	14	*	*	.	*	21
5-9	13	*	*	.	16	*	*	.	*	15	20	*	*	*	*	31
10-14	18	17	*	*	37	34	15	.	*	52	52	32	*	*	89	
15-19	61	22	.	*	85	53	19	*	*	77	114	41	*	*	162	
20-29	245	109	*	18	374	130	72	*	21	225	375	181	*	39	599	
30-39	285	263	*	23	575	184	167	*	21	377	469	430	*	44	952	
40-49	413	351	11	28	803	308	213	*	36	565	721	564	19	64	1,368	
50-59	589	284	11	27	911	372	187	*	34	602	961	471	20	61	1,513	
60-64	400	141	*	18	564	286	108	*	21	421	686	249	11	39	985	
65-69	596	128	*	20	749	399	129	*	15	552	995	257	14	35	1,301	
70-79	1,828	275	13	48	2,164	1,184	278	17	45	1,524	3,012	553	30	93	3,688	
80+	1,296	155	*	33	1,487	992	223	*	32	1,253	2,288	378	*	65	2,740	
0-19	102	43	*	*	152	98	43	*	*	151	200	86	*	14	303	
20-44	720	540	*	55	1,324	462	353	*	57	880	1,182	893	17	112	2,204	
45-64	1,212	608	24	59	1,903	818	394	22	76	1,310	2,030	1,002	46	135	3,213	
65-74	1,442	268	11	51	1,772	939	267	18	39	1,263	2,381	535	29	90	3,035	
75+	2,278	290	10	50	2,628	1,636	363	14	53	2,066	3,914	653	24	103	4,694	
All	5,754	1,749	56	220	7,779	3,953	1,420	63	234	5,670	9,707	3,169	119	454	13,449	
MISSING CAUSE																
0-4	29	*	.	*	37	26	*	.	.	31	55	12	.	*	68	
5-9	27	10	.	*	39	22	*	.	.	27	49	15	.	*	66	
10-14	50	19	.	.	69	33	*	.	*	47	83	28	.	*	116	
15-19	60	24	.	*	89	59	25	*	*	89	119	49	*	*	178	
20-29	166	104	*	18	289	153	74	*	24	253	319	178	*	42	542	
30-39	351	240	*	19	616	255	141	*	26	430	606	381	14	45	1,046	
40-49	568	356	*	44	976	377	209	*	26	618	945	565	14	70	1,594	
50-59	644	339	16	31	1,030	449	269	*	25	749	1,093	608	22	56	1,779	
60-64	257	124	*	21	407	264	174	*	*	455	521	298	13	30	862	
65-69	153	35	.	*	195	125	78	*	*	207	278	113	*	10	402	
70-79	248	69	*	*	324	234	117	*	*	359	482	186	*	11	683	
80+	123	21	.	*	148	120	58	.	*	179	243	79	.	*	327	
0-19	166	60	.	*	234	140	44	*	*	194	306	104	*	17	428	
20-44	766	522	10	52	1,350	565	308	13	63	949	1,331	830	23	115	2,299	
45-64	1,220	641	26	81	1,968	933	559	17	47	1,556	2,153	1,200	43	128	3,524	
65-74	295	71	.	*	374	244	141	*	*	394	539	212	*	14	768	
75+	229	54	*	*	293	235	112	*	*	351	464	166	*	12	644	
All	2,676	1,348	37	158	4,219	2,117	1,164	35	128	3,444	4,793	2,512	72	286	7,663	

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 The age of the incident patient is determined as of the date of ESRD initiation.
 U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.
 *Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table A.8

Incident Rates of Reported ESRD: by Primary Diagnosis

per ten million population, 1997-2000 combined, adjusted for & grouped by age, gender, & race

DIABETES	Unadjusted rates								Rates adjusted for:							
	Male				Female				Gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	Race	
0-4	4	*	.	.	5	18	*	.	4	15	*	.	5	6	5	
5-9	.	*	.	.	*	*	.	.	*	*	.	.	*	*	*	
10-14	*	*	*	*	.	.	*	*	*	
15-19	*	*	.	.	5	17	.	.	4	13	.	.	3	6	5	
20-29	94	265	166	*	105	340	251	58	99	306	210	40	114	133	124	
30-39	432	889	1,067	203	283	748	935	146	353	812	997	173	482	341	410	
40-49	871	3,040	4,367	866	584	2,536	3,954	530	736	2,894	4,318	717	1,211	882	1,042	
50-59	2,185	9,774	13,946	3,296	1,749	9,259	13,471	2,258	2,013	9,822	14,158	2,891	3,396	2,921	3,153	
60-64	3,790	15,260	18,821	6,109	3,467	17,049	24,928	5,815	3,622	16,184	21,945	5,966	5,477	5,486	5,485	
65-69	4,816	15,960	16,567	8,941	4,244	19,662	26,747	7,871	4,528	17,852	21,762	8,390	6,510	6,561	6,543	
70-79	5,212	15,237	15,413	11,462	4,038	19,152	20,513	9,897	4,594	17,061	17,600	10,740	6,801	6,302	6,554	
80+	3,122	8,927	6,865	8,015	1,636	9,425	6,697	7,794	2,245	8,990	6,848	7,635	3,847	2,898	3,366	
0-19	2	6	.	.	3	10	*	.	2	8	*	.	2	3	3	
20-44	365	860	1,037	206	258	784	906	144	292	817	1,010	170	410	313	361	
45-64	2,112	8,673	11,853	2,991	1,742	8,629	12,725	2,302	2,140	9,942	14,066	3,189	3,458	3,118	3,285	
65-74	5,032	15,941	17,219	9,735	4,285	20,047	25,168	8,657	4,659	18,062	21,237	9,278	6,736	6,669	6,710	
75+	4,130	11,671	9,274	10,247	2,497	12,914	11,021	9,037	2,963	11,277	9,395	8,861	4,778	3,874	4,321	
All	1,142	2,768	3,125	1,283	1,011	3,542	3,963	1,239	1,076	3,174	3,548	1,260	1,367	1,378	1,373	
All (age adjusted)	1,166	4,030	4,792	2,010	909	4,336	5,586	1,693	1,024	4,208	5,233	1,836	1,489	1,284	1,377	
HYPERTENSION																
0-4	*	*	.	.	4	*	*	.	3	13	*	.	4	5	5	
5-9	*	*	.	.	*	*	.	.	*	*	.	.	*	*	*	
10-14	*	*	.	.	*	*	*	*	2	*	*	*	*	2	2	
15-19	7	120	.	.	8	76	.	*	7	98	.	*	21	16	19	
20-29	55	743	*	165	25	372	*	63	40	558	65	110	149	71	108	
30-39	99	1,935	257	244	51	995	137	144	74	1,445	195	193	339	175	254	
40-49	204	4,181	624	464	108	2,092	391	337	157	3,176	517	404	741	379	552	
50-59	525	6,903	1,577	1,048	319	4,007	497	786	434	5,492	1,045	956	1,397	829	1,102	
60-64	1,357	9,328	2,110	2,223	816	7,005	1,401	1,447	1,080	8,142	1,753	1,830	2,417	1,637	2,015	
65-69	2,563	10,471	3,447	3,454	1,437	8,928	2,382	2,613	1,988	9,682	2,904	3,027	3,618	2,450	3,020	
70-79	5,045	14,331	4,736	8,107	2,639	13,100	4,719	4,468	3,881	13,918	4,736	6,458	6,489	4,112	5,275	
80+	7,043	16,098	3,613	11,542	2,889	13,415	2,841	7,678	4,820	14,554	3,173	9,345	8,136	4,408	6,233	
0-19	3	35	.	.	3	24	*	*	3	30	*	*	7	6	7	
20-44	99	1,764	210	246	50	909	147	135	71	1,321	183	186	316	160	235	
45-64	579	6,620	1,394	1,047	352	4,007	628	766	534	5,720	1,121	1,056	1,522	937	1,219	
65-74	3,340	11,495	3,826	4,855	1,842	10,353	3,386	3,122	2,600	11,080	3,685	4,097	4,514	3,025	3,753	
75+	6,572	16,261	4,451	10,822	2,965	13,826	3,674	6,593	4,730	14,822	3,784	8,813	7,947	4,479	6,176	
All	713	2,718	541	755	477	2,252	437	574	593	2,473	488	661	962	713	835	
All (age adjusted)	780	3,901	915	1,310	396	2,766	657	834	554	3,302	778	1,036	1,114	636	838	
GLOMERULONEPHRITIS																
0-4	8	*	.	*	7	*	.	*	7	9	.	*	9	7	8	
5-9	16	20	*	*	15	32	*	*	16	26	*	*	16	18	17	
10-14	28	65	*	*	28	95	*	*	28	80	*	34	33	37	35	
15-19	77	262	*	166	61	210	*	132	69	236	*	149	104	83	93	
20-29	170	567	306	397	104	401	331	253	136	484	320	320	231	149	189	
30-39	211	864	459	497	111	552	357	373	160	703	407	435	307	180	242	
40-49	284	1,266	870	519	146	679	438	516	215	982	663	521	430	234	329	
50-59	429	1,565	979	817	239	763	721	516	338	1,153	878	678	601	326	459	
60-64	647	1,487	1,350	1,021	315	913	738	688	478	1,194	1,032	852	776	410	589	
65-69	847	1,561	1,557	1,486	446	1,043	1,008	957	642	1,296	1,289	1,216	970	548	754	
70-79	1,225	1,514	1,525	2,220	544	1,117	1,258	1,339	883	1,303	1,380	1,787	1,313	656	978	
80+	1,214	1,220	*	2,324	415	826	*	1,386	782	1,000	*	1,841	1,211	505	850	
0-19	32	91	66	54	28	86	*	52	30	88	52	55	41	36	38	
20-44	204	794	435	470	113	503	355	339	156	644	399	400	290	172	230	
45-64	435	1,515	1,079	726	229	795	640	580	350	1,154	893	690	616	332	470	
65-74	987	1,571	1,605	1,713	477	1,091	1,112	1,148	731	1,330	1,368	1,451	1,105	590	842	
75+	1,271	1,320	927	2,423	485	935	889	1,330	837	1,081	808	1,857	1,269	563	909	
All	310	700	448	476	174	472	339	373	241	580	393	423	366	223	293	
All (age adjusted)	320	839	585	614	161	515	414	428	232	670	496	510	393	212	294	

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.8 (continued)
Incident Rates of Reported ESRD: by Primary Diagnosis
per ten million population, 1997-2000 combined, adjusted for & grouped by age, gender, & race

CYSTIC KIDNEY	Unadjusted rates				Female				Rates adjusted for:				Race		Gender			
	Male	White	Black	N Am	Asian	White	Black	N Am	Asian	Gender	White	Black	N Am	Asian	Male	Female	& Race	
0-4	7	*	.	.	*	10	*	.	.	*	9	*	.	.	*	7	9	8
5-9	*	*	*	.	.	5	*	.	.	.	4	*	*	.	3	4	4	
10-14	7	*	.	.	*	8	*	*	.	.	7	*	*	*	6	7	7	
15-19	5	*	.	.	.	7	*	.	*	.	6	*	.	*	5	7	6	
20-29	7	*	.	.	*	9	*	.	*	.	8	6	.	*	7	8	8	
30-39	45	41	*	.	28	28	42	.	*	.	35	41	*	16	43	28	35	
40-49	150	155	*	.	110	108	157	*	37	130	160	90	76	151	114	132		
50-59	218	259	*	.	134	189	227	*	118	204	243	*	128	219	192	205		
60-64	178	275	*	.	165	171	218	*	197	175	245	*	179	190	177	184		
65-69	183	268	.	.	219	161	168	*	*	172	217	*	159	194	158	176		
70-79	180	357	*	.	230	134	214	*	166	156	287	*	189	206	144	174		
80+	141	390	.	.	*	60	81	*	*	95	221	*	*	158	61	108		
0-19	5	4	*	*	*	7	*	*	*	6	4	*	*	5	7	6		
20-44	49	44	*	.	31	33	44	*	*	37	44	*	20	44	31	37		
45-64	198	238	145	145	171	214	*	108	186	231	117	134	202	176	189			
65-74	178	299	*	.	234	151	188	*	144	164	246	*	194	195	155	175		
75+	165	386	*	.	*	88	140	*	*	115	247	*	79	177	86	130		
All	84	81	42	53	70	75	27	37	77	78	35	45	82	69	75			
All (age adjusted)	84	114	60	68	67	86	35	43	75	98	47	55	86	67	76			
OTHER UROLOGIC																		
0-4	*	*	.	.	*	*	.	.	*	*	.	.	*	*	.	.	1	
5-9	*	*	.	.	5	*	.	.	4	*	.	.	3	4	4			
10-14	9	*	.	*	10	*	.	*	9	*	.	*	9	9	9			
15-19	12	*	.	*	18	*	.	.	15	13	.	*	12	16	14			
20-29	20	17	*	*	28	14	*	*	24	15	*	*	19	25	22			
30-39	25	46	*	*	31	13	*	*	28	29	*	13	27	28	27			
40-49	32	57	*	*	37	45	*	*	34	51	*	*	22	35	37	36		
50-59	67	166	*	54	56	106	*	76	63	143	128	65	83	65	74			
60-64	170	264	*	*	82	113	*	*	125	187	*	111	182	86	133			
65-69	222	481	*	262	102	228	*	*	161	352	*	185	257	119	186			
70-79	400	733	*	312	121	172	*	201	262	455	*	257	450	131	287			
80+	556	854	*	481	86	248	.	*	315	541	*	350	587	110	343			
0-19	6	7	.	*	8	7	.	*	7	7	.	*	6	8	7			
20-44	24	34	*	15	30	20	*	11	27	27	*	13	25	28	26			
45-64	74	147	*	62	56	87	*	52	72	132	123	66	96	64	80			
65-74	270	540	*	283	111	214	*	153	190	377	*	221	309	127	216			
75+	526	874	*	397	101	201	*	202	312	530	*	319	571	116	338			
All	71	86	47	40	42	46	35	29	56	65	41	35	72	42	57			
All (age adjusted)	77	137	76	65	39	55	45	40	54	89	59	50	82	40	57			
OTHER CAUSE																		
0-4	75	122	*	*	41	66	*	*	58	93	*	31	79	44	61			
5-9	35	53	*	*	26	42	*	*	31	48	*	*	37	28	32			
10-14	64	102	*	*	48	110	*	76	55	106	*	62	68	57	62			
15-19	78	140	*	*	73	202	*	145	75	172	119	99	85	93	89			
20-29	108	397	*	115	104	611	185	184	106	508	139	151	145	172	160			
30-39	125	1,124	270	83	123	974	220	181	124	1,044	244	133	251	235	243			
40-49	203	1,615	443	123	186	1,022	391	156	196	1,318	426	141	386	295	338			
50-59	412	1,646	761	269	355	999	795	232	393	1,316	792	255	577	443	508			
60-64	764	1,745	1,519	395	571	1,290	*	281	665	1,512	959	335	881	650	762			
65-69	1,148	1,742	*	896	719	1,299	1,374	552	930	1,515	1,189	721	1,214	793	999			
70-79	1,631	2,348	1,204	1,250	923	1,549	1,133	735	1,280	1,941	1,142	1,008	1,720	1,002	1,353			
80+	1,701	2,098	*	1,322	667	1,247	*	751	1,138	1,651	697	976	1,672	736	1,194			
0-19	63	103	82	35	47	105	67	64	55	105	74	51	68	55	61			
20-44	128	911	199	98	125	840	229	179	125	870	217	140	226	216	221			
45-64	418	1,698	829	248	351	1,069	616	208	420	1,383	769	249	617	464	538			
65-74	1,296	2,019	1,234	974	795	1,374	1,263	610	1,046	1,716	1,256	797	1,389	869	1,123			
75+	1,772	2,200	927	1,410	797	1,425	711	781	1,225	1,756	785	1,031	1,740	844	1,282			
All	333	822	308	172	260	697	295	191	296	756	301	182	387	315	350			
All (age adjusted)	347	1,017	426	250	236	755	371	217	283	875	396	228	423	298	351			

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 The age of the incident patient is determined as of the date of ESRD initiation.
 U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.
 *Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table A.8 (continued)

Incident Rates of Reported ESRD: by Primary Diagnosis

per ten million population, 1997-2000 combined, adjusted for & grouped by age, gender, & race

UNKNOWN CAUSE	Unadjusted rates								Rates adjusted for:							
	Male				Female				Gender				Race		Gender	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	& Race	
0-4	3	*	.	*	*	*	.	*	2	*	.	*	4	*	3	
5-9	4	*	*	.	*	*	.	*	3	*	*	*	4	4	4	
10-14	6	27	*	*	11	25	.	*	9	26	*	*	9	13	11	
15-19	19	36	.	*	18	32	*	*	18	34	*	*	21	20	20	
20-29	42	106	*	56	23	66	*	60	32	86	*	59	50	30	40	
30-39	41	250	*	64	27	141	*	53	34	194	*	59	69	43	55	
40-49	60	386	181	91	45	202	*	104	53	296	161	99	106	68	86	
50-59	122	549	299	145	74	288	*	161	99	420	263	155	181	108	144	
60-64	234	791	*	296	153	452	*	295	192	618	431	300	309	200	253	
65-69	388	799	*	437	224	600	*	243	304	697	700	337	444	278	359	
70-79	741	1,326	1,044	789	364	903	1,070	533	558	1,133	1,079	660	838	451	640	
80+	1,190	1,890	*	1,322	465	1,288	*	924	810	1,578	*	1,120	1,266	587	919	
0-19	8	18	*	*	8	18	*	*	8	18	*	11	9	10	9	
20-44	44	209	*	65	28	124	*	61	35	165	47	63	65	41	53	
45-64	125	554	316	153	81	289	266	172	113	447	305	182	198	123	159	
65-74	495	953	679	628	267	688	910	350	382	835	811	506	570	333	448	
75+	1,045	1,724	927	993	448	1,178	830	766	759	1,483	814	961	1,170	563	860	
All	131	266	119	107	87	195	131	106	108	229	125	106	147	102	124	
All (age adjusted)	142	375	192	166	75	232	189	135	102	297	190	147	168	93	124	
MISSING CAUSE																
0-4	9	*	.	*	9	*	.	.	9	11	0	*	10	8	9	
5-9	8	16	.	*	7	*	.	.	8	12	0	*	9	7	8	
10-14	16	31	.	.	11	*	.	*	13	23	0	*	17	12	15	
15-19	19	39	.	*	20	42	*	*	19	41	*	*	22	23	22	
20-29	28	101	*	56	27	68	*	69	28	84	*	62	39	34	36	
30-39	50	228	*	53	37	119	*	65	44	172	96	59	73	49	61	
40-49	83	392	*	143	55	199	*	75	69	292	112	108	125	75	99	
50-59	134	655	435	167	89	415	*	118	109	527	273	141	200	132	165	
60-64	150	696	*	346	141	729	*	*	145	709	503	229	228	219	223	
65-69	99	219	.	*	70	363	*	*	85	293	*	97	116	107	112	
70-79	100	333	*	*	72	380	*	*	86	362	*	85	131	112	122	
80+	113	256	.	*	56	335	.	*	81	291	.	*	126	90	108	
0-19	13	25	.	*	12	19	*	*	12	21	*	13	14	13	13	
20-44	46	202	54	61	35	108	71	68	39	153	64	64	66	45	55	
45-64	126	584	342	209	92	410	205	106	111	524	297	162	194	143	168	
65-74	101	252	.	*	69	364	*	*	85	312	*	71	120	107	114	
75+	105	321	*	*	64	364	*	*	83	325	*	107	130	99	114	
All	61	205	78	77	46	160	73	58	54	181	76	67	79	62	71	
All (age adjusted)	61	246	101	87	44	181	90	58	52	214	96	71	82	59	70	

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.9
Mean Age at Start of ESRD Therapy
by demographic characteristics & primary diagnosis

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	1	2	2	1	1	2	2	1	1	1
5-9	7	7	7	7	7	7	7	7	7	7
10-14	12	12	12	12	12	12	12	12	12	12
15-19	17	17	17	17	17	17	17	17	17	17
20-24	22	22	22	22	22	22	22	22	22	22
25-29	27	27	27	27	27	27	27	27	27	27
30-34	32	32	32	32	32	32	32	32	32	32
35-39	37	37	37	37	37	37	37	37	37	37
40-44	42	42	42	42	42	42	42	42	42	42
45-49	47	47	47	47	47	47	47	47	47	47
50-54	52	52	52	52	52	52	52	52	52	52
55-59	57	57	57	57	57	57	57	57	57	57
60-64	62	62	62	62	62	62	62	62	62	62
65-69	67	67	67	67	67	67	67	67	67	67
70-74	72	72	72	72	72	72	72	72	72	72
75-79	77	77	77	77	77	77	77	77	77	77
80-84	82	82	82	82	82	82	82	82	82	82
85+	87	87	87	87	87	87	88	88	88	88
0-19	12	13	12	13	12	12	12	12	12	12
20-44	35	35	35	35	35	35	35	36	36	36
45-64	56	56	56	56	56	56	56	56	56	55
65-74	69	69	69	70	70	70	70	70	70	70
75+	80	80	80	80	80	80	80	80	80	80
Male	58	58	58	58	59	59	60	60	61	61
Female	60	60	60	60	61	61	62	62	62	62
Unknown	47	44	36	64	53	65	15	.	30	60
White	60	61	61	61	62	62	63	63	64	64
Black	56	57	57	56	56	57	57	57	57	57
Native American	56	58	58	56	56	56	57	57	57	58
Asian	57	56	57	58	60	60	60	60	61	61
Other/unknown	48	49	51	50	54	54	55	53	55	52
†Hispanic	47	49	52	54	56	57	57	58	58	58
†Non-Hispanic	59	60	60	59	60	61	61	61	62	62
Diabetes	59	59	60	60	60	61	62	62	62	62
Hypertension	65	65	65	65	65	65	66	66	66	67
Glomerulonephritis	52	52	52	53	52	53	53	53	54	53
Cystic kidney	54	54	54	55	54	54	55	54	55	55
Other urologic	61	60	59	59	59	60	60	61	61	62
Other cause	52	53	52	53	53	54	55	55	56	56
Unknown cause	61	62	60	60	62	62	63	62	64	63
Missing disease	48	51	59	52	54	54	51	50	51	48
U.S.	59	59	60	60	60	60	61	61	61	61
U.S. territories	57	53	57	55	55	55	56	56	58	58
Puerto Rico	57	59	59	58	58	59	60	59	60	59
Foreign	45	46	47	47	48	48	45	52	55	54
Unknown	46	48	49	50	48	46	38	42	43	51
All	59	59	59	59	59	60	61	61	61	61

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients with unknown age are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

." Zero values in this cell.

Table A.10

Incidence of Reported ESRD, by Primary Diagnosis: All Patients, Row Percent

1996-2000 combined, by detailed primary diagnosis

	Total Patients	Percent Incident	Median Age	Percent Male	Percent White	Black	N Am	Asian	Tx 1st yr	Died 1st yr
All ESRD (reference)	434,120	100.0	64	53.4	63.1	29.7	1.4	3.5	5.2	22.8
Diabetes	187,340	44.3	63	48.7	62.7	28.9	2.2	3.7	3.0	22.4
Type 1 (juvenile)	25,519	6.0	48	52.7	71.9	22.8	1.3	2.1	11.9	16.6
Type 2 (adult-onset or unspecified)	161,821	38.2	65	48.0	61.3	29.9	2.4	3.9	1.5	23.3
Glomerulonephritis (GN)	41,262	9.7	54	61.2	66.0	24.6	1.2	5.6	12.1	12.7
Focal glomerulosclerosis, focal GN	10,080	2.4	48	61.3	58.0	36.5	0.9	2.9	13.9	9.7
Membranous nephropathy	2,073	0.5	59	67.0	68.9	25.9	0.9	2.6	11.2	12.5
Membranoproliferative GN, types 1 & 2	1,711	0.4	49	59.4	72.6	18.3	2.0	4.4	17.1	11.0
IgA nephropathy, Berger's disease	3,277	0.8	42	68.2	75.1	7.2	1.7	12.8	29.2	5.0
IgM nephropathy	325	0.1	46	65.8	74.8	9.5	1.2	12.9	26.8	4.6
Rapidly progressive GN	1,741	0.4	63	51.2	79.5	13.2	1.7	3.0	6.8	19.3
Goodpasture's Syndrome	527	0.1	55	46.3	89.6	6.8	1.1	1.3	7.0	19.2
Post-infectious GN, SBE	377	0.1	54	68.2	77.7	14.3	3.2	3.4	9.3	18.0
Glomerulonephritis	19,890	4.7	58	61.1	65.0	24.1	1.2	6.6	8.3	15.0
Other proliferative GN	1,261	0.3	54	54.2	72.3	19.8	1.3	3.4	12.5	12.5
Secondary GN/vasculitis	10,052	2.4	46	32.4	60.5	32.5	1.3	3.2	7.1	18.5
Lupus erythematosus (SLE nephritis)	5,028	1.2	38	17.8	43.0	47.7	1.1	4.6	8.8	12.3
Polyarteritis	250	0.1	64	53.2	80.0	13.2	1.6	3.6	3.2	24.0
Wegener's granulomatosis	1,162	0.3	64	59.8	89.9	6.6	1.0	1.4	5.7	21.4
Henoch-Schonlein syndrome	167	.	30	53.9	81.4	9.0	2.4	5.4	25.7	7.2
Vasculitis and its derivatives	1,099	0.3	68	47.2	84.4	9.9	2.7	1.5	2.6	28.0
Scleroderma	842	0.2	57	23.2	77.0	19.6	1.1	1.7	2.6	37.4
Hemolytic uremic syndrome	781	0.2	46	34.1	77.0	19.6	0.9	1.2	9.5	18.6
Nephropathy from heroin/related abuse	271	0.1	44	72.0	29.9	66.4	1.1	1.5	1.8	14.4
Secondary GN, other	452	0.1	54	59.5	62.6	30.8	1.1	3.5	4.9	24.3
Interstitial nephritis/pyelonephritis	16,653	3.9	65	56.1	79.6	15.4	0.7	2.6	7.3	22.5
Chronic pyelonephritis, reflux nephritis	2,396	0.6	45	39.6	85.9	9.0	0.9	2.2	21.7	11.2
Analgesic abuse	960	0.2	67	38.2	78.1	17.4	0.6	2.5	4.5	19.1
Nephropathy caused by other agents	2,336	0.6	62	58.3	78.9	17.6	0.4	1.5	6.0	28.3
Nephrolithiasis, obstruction, gouty	5,644	1.3	69	72.3	77.5	16.7	0.7	3.0	2.4	25.6
Nephrocalcinosis	296	0.1	67	49.7	80.4	13.2	0.3	3.4	8.4	19.6
Chronic interstitial nephritis	4,239	1.0	65	48.3	78.7	16.2	0.7	2.9	7.9	20.9
Acute interstitial nephritis	782	0.2	69	49.0	84.3	12.8	0.6	1.4	2.3	31.2
Hypertensive/large vessel disease	112,185	26.5	70	56.6	57.3	37.6	0.6	3.1	1.8	25.6
Hypertension (no primary renal disease)	99,131	23.4	69	56.4	52.7	41.8	0.6	3.4	2.0	24.2
Renal artery stenosis or occlusion	8,740	2.1	74	54.4	91.5	6.4	0.4	1.3	0.5	36.6
Cholesterol emboli, renal emboli	4,314	1.0	73	66.3	94.5	3.5	0.4	1.2	0.5	36.6
Cystic/hereditary/congenital diseases	14,075	3.3	50	57.0	80.6	13.9	0.6	2.4	24.1	6.4
Polycystic kidneys, adult (dominant)	9,834	2.3	54	53.8	81.8	13.5	0.4	2.5	19.6	6.5
Polycystic, infantile (recessive)	233	0.1	15	46.8	84.1	10.7	.	1.3	37.3	8.2
Medullary cystic, including nephronophthisis	220	0.1	25	48.6	82.7	10.0	0.9	3.6	43.2	3.2
Alport's, other hereditary/familial disease	1,044	0.2	36	66.0	85.4	9.4	0.9	2.2	32.7	2.5
Tuberous sclerosis	133	.	56	51.9	71.4	22.6	1.5	1.5	10.5	21.8
Cystinosis	57	.	16	40.4	80.7	10.5	3.5	1.8	49.1	7.0
Primary oxalosis	49	.	44	40.8	81.6	4.1	2.0	4.1	34.7	6.1
Fabry's disease	78	.	43	92.3	87.2	5.1	5.1	.	23.1	9.0
Congenital nephrotic syndrome	268	0.1	23	55.2	67.9	20.9	0.7	4.1	29.1	11.6
Drash syndrome, mesangial sclerosis	33	.	35	57.6	75.8	12.1	.	3.0	18.2	9.1
Congenital obstructive uropathy	1,175	0.3	23	75.1	75.3	17.4	0.8	2.7	34.6	7.3
Renal hypoplasia, dysplasia	831	0.2	13	57.0	72.6	18.7	1.2	1.9	39.4	4.0
Prune belly syndrome	120	.	12	97.5	70.8	25.8	.	0.8	37.5	5.0
Neoplasms/tumors	8,189	1.9	69	61.1	76.9	19.9	0.6	1.4	0.9	48.9
Renal or urological neoplasms	2,351	0.6	69	73.4	79.3	18.1	0.6	0.8	1.2	40.0
Multiple myeloma	4,155	1.0	69	55.7	74.0	22.4	0.5	1.9	.	57.1
Light chain nephropathy	532	0.1	70	60.3	79.7	17.1	0.8	1.3	1.3	41.5
Amyloidosis	1,151	0.3	67	55.7	81.1	15.7	0.9	0.9	3.3	41.3
Miscellaneous conditions	16,759	4.0	58	63.0	59.9	36.3	0.6	1.4	3.2	35.5
Complication post-bone marrow/other tx	485	0.1	54	64.1	87.6	8.0	0.6	1.6	16.7	23.1
Sickle cell disease/anemia or trait	492	0.1	41	50.4	3.7	95.5	0.2	0.6	1.8	24.2
AIDS nephropathy	4,224	1.0	39	70.8	7.2	89.3	0.6	0.2	.	33.4
Traumatic/surgical loss of kidney(s)	485	0.1	67	67.8	80.2	16.9	0.2	1.4	2.7	25.6
Hepatorenal syndrome	744	0.2	54	68.1	77.4	14.7	2.6	2.4	12.1	53.4
Tubular necrosis (no recovery)	5,752	1.4	70	59.1	82.4	14.4	0.6	1.4	0.7	39.3
Post-partum failure, other renal disorders	4,577	1.1	66	60.5	78.3	17.1	0.6	2.4	6.6	33.3
Etiology uncertain	16,852	4.0	68	57.7	69.9	23.1	0.9	3.4	4.7	28.0
Missing	10,753	.	51	54.6	56.2	30.2	0.9	3.5	32.0	16.7

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 "." Zero values in this cell.

Table A.11
Incidence of Reported ESRD, by Primary Diagnosis: All Patients, Column Percent
 1996-2000 combined, by detailed primary diagnosis

	Total Patients	Counts				Percent			
		White	Black	N Am	Asian	White	Black	N Am	Asian
All ESRD (reference)	434,120	273,918	129,107	6,122	15,063	100.0	100.0	100.0	100.0
Diabetes	187,340	117,555	54,156	4,208	6,871	43.9	43.0	69.8	46.8
Type 1, juvenile type	25,519	18,346	5,825	325	534	6.8	4.6	5.4	3.6
Type 2, adult-onset or unspecified type	161,821	99,209	48,331	3,883	6,337	37.0	38.4	64.4	43.1
Glomerulonephritis	41,262	27,215	10,170	508	2,300	10.2	8.1	8.4	15.7
Focal glomerulosclerosis, focal GN	10,080	5,843	3,682	89	290	2.2	2.9	1.5	2.0
Membranous nephropathy	2,073	1,429	536	19	54	0.5	0.4	0.3	0.4
Membranoproliferative GN, types 1&2	1,711	1,243	313	34	76	0.5	0.2	0.6	0.5
IgA nephropathy, Berger's disease	3,277	2,462	237	56	418	0.9	0.2	0.9	2.8
IgM nephropathy	325	243	31	*	42	0.1	.	0.1	0.3
Rapidly progressive GN	1,741	1,384	230	29	53	0.5	0.2	0.5	0.4
Goodpasture's Syndrome	527	472	36	*	*	0.2	.	0.1	.
Post infectious GN, SBE	377	293	54	12	13	0.1	.	0.2	0.1
Glomerulonephritis (GN)	19,890	12,934	4,801	243	1,304	4.8	3.8	4.0	8.9
Other proliferative GN	1,261	912	250	16	43	0.3	0.2	0.3	0.3
Secondary GN/vasculitis	10,052	6,082	3,271	131	325	2.3	2.6	2.2	2.2
Lupus erythematosus (SLE nephritis)	5,028	2,160	2,400	57	231	0.8	1.9	0.9	1.6
Polyarteritis	250	200	33	*	*	0.1	.	0.1	0.1
Wegener's granulomatosis	1,162	1,045	77	12	16	0.4	0.1	0.2	0.1
Henoch-Schonlein syndrome	167	136	15	*	*	0.1	.	0.1	0.1
Vasculitis and its derivatives	1,099	928	109	30	17	0.3	0.1	0.5	0.1
Scleroderma	842	648	165	*	14	0.2	0.1	0.1	0.1
Hemolytic uremic syndrome	781	601	153	*	*	0.2	0.1	0.1	0.1
Nephropathy from heroin /related abuse	271	81	180	*	*	.	0.1	.	.
Secondary GN, other	452	283	139	*	16	0.1	0.1	0.1	0.1
Interstitial nephritis/pyelonephritis	16,653	13,253	2,564	113	427	4.9	2.0	1.9	2.9
Chronic pyelonephritis, reflux neph.	2,396	2,057	215	21	52	0.8	0.2	0.3	0.4
Analgesic abuse	960	750	167	*	24	0.3	0.1	0.1	0.2
Nephropathy caused by other agents	2,336	1,842	412	10	35	0.7	0.3	0.2	0.2
Nephrolithiasis, obstruction, gouty	5,644	4,372	943	39	170	1.6	0.7	0.6	1.2
Nephrocalcinosis	296	238	39	*	10	0.1	.	.	0.1
Chronic interstitial nephritis	4,239	3,335	688	31	125	1.2	0.5	0.5	0.9
Acute interstitial nephritis	782	659	100	*	11	0.2	0.1	0.1	0.1
Hypertensive/large vessel disease	112,185	64,308	42,138	671	3,491	24.0	33.5	11.1	23.8
Hypertension (no primary renal disease)	99,131	52,236	41,428	619	3,329	19.5	32.9	10.3	22.7
Renal artery stenosis or occlusion	8,740	7,997	559	33	110	3.0	0.4	0.5	0.7
Cholesterol emboli, renal emboli	4,314	4,075	151	19	52	1.5	0.1	0.3	0.4
Cystic/hereditary/congenital diseases	14,075	11,348	1,962	81	344	4.2	1.6	1.3	2.3
Polycystic kidneys, adult (dominant)	9,834	8,049	1,325	40	244	3.0	1.1	0.7	1.7
Polycystic, infantile (recessive)	233	196	25	.	*	0.1	.	.	.
Medullary cystic, including nephronphthisis	220	182	22	*	*	0.1	.	.	0.1
Alport's, other hereditary/familial disease	1,044	892	98	*	23	0.3	0.1	0.1	0.2
Tuberous sclerosis	133	95	30	*	*
Cystinosis	57	46	*	*	*
Primary oxalosis	49	40	*	*	*
Fabry's disease	78	68	*	*	.	.	.	0.1	.
Congenital nephrotic syndrome	268	182	56	*	11	0.1	.	.	0.1
Drash syndrome, mesangial sclerosis	33	25	*	.	*
Congenital obstructive uropathy	1,175	885	204	*	32	0.3	0.2	0.1	0.2
Renal hypoplasia, dysplasia	831	603	155	10	16	0.2	0.1	0.2	0.1
Prune belly syndrome	120	85	31	.	*
Neoplasms/tumors	8,189	6,296	1,628	51	115	2.4	1.3	0.8	0.8
Renal or urological neoplasms	2,351	1,864	426	15	18	0.7	0.3	0.2	0.1
Multiple myeloma	4,155	3,074	930	22	80	1.1	0.7	0.4	0.5
Light chain nephropathy	532	424	91	*	*	0.2	0.1	0.1	.
Amyloidosis	1,151	934	181	10	10	0.3	0.1	0.2	0.1
Miscellaneous conditions	16,759	10,038	6,083	108	235	3.7	4.8	1.8	1.6
Complication post bone marrow/other txp	485	425	39	*	*	0.2	.	.	0.1
Sickle cell disease/anemia or trait	492	18	470	*	*	.	0.4	.	.
AIDS nephropathy	4,224	306	3,773	24	10	0.1	3.0	0.4	0.1
Traumatic/surgical loss of kidney(s)	485	389	82	*	*	0.1	0.1	.	.
Hepatorenal syndrome	744	576	109	19	18	0.2	0.1	0.3	0.1
Tubular necrosis (no recovery)	5,752	4,739	826	33	78	1.8	0.7	0.5	0.5
Post-partum failure, other renal disorders	4,577	3,585	784	27	111	1.3	0.6	0.4	0.8
Etiology uncertain	16,852	11,779	3,885	159	581	4.4	3.1	2.6	4.0
Missing	10,753	6,044	3,250	92	374

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.12

Incidence of Reported ESRD, by Primary Diagnosis: Hispanics, Row Percent

1996-2000 combined, by detailed primary diagnosis

	Total Patients	Percent Incident	Median Age	Percent Males	Percent White	Black	N Am	Asian	Tx 1st yr	Died 1st yr
All ESRD (reference)	49,705	100.0	60	53.1	78.7	4.2	1.7	1.8	3.3	17.3
Diabetes	29,649	60.1	62	50.0	81.6	3.5	1.4	1.5	1.2	18.1
Type 1, juvenile type	2,708	5.5	51	52.1	77.1	4.7	1.6	1.9	4.7	15.6
Type 2, adult-onset or unspecified type	26,941	54.6	63	49.8	82.1	3.4	1.4	1.4	0.9	18.4
Glomerulonephritis	4,485	9.1	43	59.9	75.2	5.1	1.6	2.1	11.1	8.0
Focal glomerulosclerosis, focal GN	849	1.7	40	60.1	76.6	6.6	2.1	1.6	15.4	5.7
Membranous nephropathy	179	0.4	52	69.8	72.6	8.4	2.8	1.1	11.2	8.4
Membranoproliferative GN, types 1&2	204	0.4	42	59.8	75.0	6.4	1.5	1.0	13.2	9.8
IgA nephropathy, Berger's disease	376	0.8	38	56.4	77.4	2.7	1.9	2.7	17.6	3.7
IgM nephropathy	31	0.1	38	54.8	83.9	3.2	3.2	3.2	19.4	.
Rapidly progressive GN	169	0.3	48	40.8	72.8	7.7	1.2	1.2	6.5	11.2
Goodpasture's Syndrome	34	0.1	40	23.5	82.4	.	.	2.9	11.8	11.8
Post infectious GN, SBE	39	0.1	48	53.8	87.2	2.6	.	5.1	7.7	15.4
Glomerulonephritis (GN)	2,477	5.0	45	61.7	74.8	4.5	1.3	2.1	8.7	9.0
Other proliferative GN	127	0.3	39	58.3	65.4	5.5	1.6	3.9	11.0	6.3
Secondary GN/vasculitis	1,163	2.4	37	26.1	76.3	3.5	2.6	1.4	7.0	10.5
Lupus erythematosus (SLE nephritis)	795	1.6	33	17.1	75.0	3.6	2.3	1.3	7.8	8.2
Polyarteritis	22	.	53	40.9	77.3	.	4.5	.	9.1	.
Wegener's granulomatosis	74	0.2	56	67.6	75.7	4.1	2.7	2.7	4.1	17.6
Henoch-Schonlein syndrome	19	.	20	52.6	68.4	.	5.3	10.5	31.6	.
Vasculitis and its derivatives	92	0.2	56	43.5	87.0	3.3	1.1	.	3.3	15.2
Scleroderma	62	0.1	52	17.7	88.7	3.2	.	1.6	6.5	25.8
Hemolytic uremic syndrome	45	0.1	35	28.9	73.3	2.2	8.9	.	2.2	13.3
Nephropathy from heroin /related abuse	22	.	38	72.7	63.6	9.1	9.1	4.5	.	.
Secondary GN, other	32	0.1	48	56.3	71.9	3.1	3.1	.	.	25.0
Interstitial nephritis/pyelonephritis	1,208	2.4	60	58.5	75.7	3.6	1.2	3.3	5.0	20.9
Chronic pyelonephritis, reflux neph.	199	0.4	33	38.7	79.4	2.5	0.5	2.5	12.1	9.0
Analgesic abuse	60	0.1	65	48.3	73.3	1.7	.	11.7	5.0	16.7
Nephropathy caused by other agents	122	0.2	58	58.2	72.1	2.5	0.8	3.3	4.1	31.1
Nephrolithiasis, obstruction, gouty	502	1.0	66	73.5	74.7	5.2	1.4	2.6	1.0	24.9
Nephrocalcinosis	15	.	58	46.7	53.3	.	.	13.3	6.7	26.7
Chronic interstitial nephritis	258	0.5	59	48.4	77.1	3.1	1.6	3.1	8.9	15.5
Acute interstitial nephritis	52	0.1	59	55.8	82.7	1.9	1.9	1.9	0.0	32.7
Hypertensive/large vessel disease	8,171	16.6	65	58.9	75.5	6.1	2.6	2.8	2.6	19.3
Hypertension (no primary renal disease)	7,781	15.8	64	59.2	75.3	6.3	2.6	2.6	2.7	18.7
Renal artery stenosis or occlusion	285	0.6	72	46.7	81.1	2.5	3.2	5.3	0.4	30.5
Cholesterol emboli, renal emboli	105	0.2	73	66.7	76.2	1.9	4.8	5.7	1.0	32.4
Cystic/hereditary/congenital diseases	1,324	2.7	44	58.0	77.5	4.6	1.3	1.8	14.7	4.5
Polycystic kidneys, adult (dominant)	802	1.6	52	55.4	79.7	4.5	1.4	1.9	9.0	4.9
Polycystic, infantile (recessive)	34	0.1	11	44.1	91.2	2.9	.	.	23.5	2.9
Medullary cystic, including nephronophthisis	19	.	16	52.6	73.7	5.3	.	5.3	36.8	5.3
Alport's, other hereditary/familial disease	94	0.2	24	68.1	76.6	5.3	1.1	3.2	24.5	1.1
Tuberous sclerosis	14	.	67	64.3	64.3	28.6	.	.	7.1	21.4
Cystinosis	*	.	54	33.3	.	.	33.3	.	33.3	.
Primary oxalosis	*	.	19	.	100.0	.	.	.	66.7	.
Fabry's disease	*	.	38	88.9	55.6	.	22.2	.	.	11.1
Congenital nephrotic syndrome	35	0.1	4	48.6	68.6	2.9	.	.	20.0	5.7
Drash syndrome, mesangial sclerosis	*	.	11	57.1	42.9	14.3	.	.	28.6	.
Congenital obstructive uropathy	138	0.3	18	77.5	72.5	5.1	0.7	2.2	25.4	4.3
Renal hypoplasia, dysplasia	149	0.3	11	48.3	75.2	2.0	0.7	1.3	20.8	3.4
Prune belly syndrome	17	.	12	100.0	82.4	11.8	.	.	29.4	.
Neoplasms/tumors	483	1.0	66	61.7	78.9	5.4	2.9	1.2	1.0	45.3
Renal or urological neoplasms	148	0.3	69	75.7	73.6	6.8	2.0	2.0	.	41.9
Multiple myeloma	231	0.5	66	55.0	82.7	4.3	2.2	0.9	.	53.7
Light chain nephropathy	29	0.1	58	44.8	65.5	6.9	10.3	3.4	.	41.4
Amyloidosis	75	0.2	65	61.3	82.7	5.3	4.0	.	6.7	28.0
Miscellaneous conditions	1,065	2.2	51	64.8	67.7	6.9	2.2	1.7	4.3	31.2
Complication post bone marrow/other txp	23	.	44	60.9	73.9	.	.	.	21.7	13.0
Sickle cell disease/anemia or trait	12	.	33	50.0	58.3	33.3	8.3	.	8.3	25.0
AIDS nephropathy	264	0.5	38	75.4	45.8	13.3	2.7	1.5	.	36.7
Traumatic/surgical loss of kidney(s)	27	0.1	53	63.0	74.1	7.4	.	3.7	.	11.1
Hepatorenal syndrome	95	0.2	55	73.7	72.6	3.2	3.2	2.1	15.8	44.2
Tubular necrosis (no recovery)	315	0.6	65	62.2	74.0	4.4	2.5	0.6	0.3	35.6
Post-partum failure, other renal disorders	329	0.7	57	57.1	77.2	4.6	1.2	2.7	7.3	21.9
Etiology uncertain	1,763	3.6	49	61.3	75.3	4.2	1.8	1.4	5.3	15.2
Missing	394	.	45	53.0	36.0	1.8	0.5	0.5	26.4	11.7

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.13

Incidence of Reported ESRD, by Primary Diagnosis: Hispanics, Column Percent

1996-2000 combined, by detailed primary diagnosis

	Total Patients	Counts				Percent			
		White	Black	N Am	Asian	White	Black	N Am	Asian
All ESRD (reference)	49,705	39,137	2,093	845	888	100.0	100.0	100.0	100.0
Diabetes	29,649	24,197	1,042	428	439	62.1	50.0	50.8	49.5
Type 1, juvenile type	2,708	2,087	128	42	52	5.4	6.1	5.0	5.9
Type 2, adult-onset or unspecified type	26,941	22,110	914	386	387	56.7	43.8	45.8	43.7
Glomerulonephritis	4,485	3,371	228	71	92	8.6	10.9	8.4	10.4
Focal glomerulosclerosis, focal GN	849	650	56	18	14	1.7	2.7	2.1	1.6
Membranous nephropathy	179	130	15	*	*	0.3	0.7	0.6	0.2
Membranoproliferative GN, types 1&2	204	153	13	*	*	0.4	0.6	0.4	0.2
IgA nephropathy, Berger's disease	376	291	10	*	10	0.7	0.5	0.8	1.1
IgM nephropathy	31	26	*	*	*	0.1	.	0.1	0.1
Rapidly progressive GN	169	123	13	*	*	0.3	0.6	0.2	0.2
Goodpasture's Syndrome	34	28	.	.	*	0.1	.	.	0.1
Post infectious GN, SBE	39	34	*	.	*	0.1	.	.	0.2
Glomerulonephritis (GN)	2,477	1,853	112	33	53	4.8	5.4	3.9	6.0
Other proliferative GN	127	83	*	*	*	0.2	0.3	0.2	0.6
Secondary GN/vasculitis	1,163	887	41	30	16	2.3	2.0	3.6	1.8
Lupus erythematosus (SLE nephritis)	795	596	29	18	10	1.5	1.4	2.1	1.1
Polyarteritis	22	17	.	*	.	.	.	0.1	.
Wegener's granulomatosis	74	56	*	*	*	0.1	0.1	0.2	0.2
Henoch-Schonlein syndrome	19	13	.	*	*	.	.	0.1	0.2
Vasculitis and its derivatives	92	80	*	*	.	0.2	0.1	0.1	.
Scleroderma	62	55	*	.	*	0.1	0.1	.	0.1
Hemolytic uremic syndrome	45	33	*	*	.	0.1	.	0.5	.
Nephropathy from heroin /related abuse	22	14	*	*	*	.	0.1	0.2	0.1
Secondary GN, other	32	23	*	*	.	0.1	.	0.1	.
Interstitial nephritis/pyelonephritis	1,208	915	44	14	40	2.3	2.1	1.7	4.5
Chronic pyelonephritis, reflux neph.	199	158	*	*	*	0.4	0.2	0.1	0.6
Analgesic abuse	60	44	*	.	*	0.1	.	.	0.8
Nephropathy caused by other agents	122	88	*	*	*	0.2	0.1	0.1	0.5
Nephrolithiasis, obstruction, gouty	502	375	26	*	13	1.0	1.2	0.8	1.5
Nephrocalcinosis	15	*	.	.	*	.	.	.	0.2
Chronic interstitial nephritis	258	199	*	*	*	0.5	0.4	0.5	0.9
Acute interstitial nephritis	52	43	*	*	*	0.1	.	0.1	0.1
Hypertensive/large vessel disease	8,171	6,170	497	215	226	15.8	23.8	25.5	25.5
Hypertension (no primary renal disease)	7,781	5,859	488	201	205	15.0	23.4	23.8	23.1
Renal artery stenosis or occlusion	285	231	*	*	15	0.6	0.3	1.1	1.7
Cholesterol emboli, renal emboli	105	80	*	*	*	0.2	0.1	0.6	0.7
Cystic/hereditary/congenital diseases	1,324	1,026	61	17	24	2.6	2.9	2.0	2.7
Polycystic kidneys, adult (dominant)	802	639	36	11	15	1.6	1.7	1.3	1.7
Polycystic, infantile (recessive)	34	31	*	.	.	0.1	.	.	.
Medullary cystic, including nephronphthisis	19	14	*	.	*	.	.	.	0.1
Alport's, other hereditary/familial disease	94	72	*	*	*	0.2	0.2	0.1	0.3
Tuberous sclerosis	14	*	*	.	.	.	0.2	.	.
Cystinosis	*	.	.	*	.	.	.	0.1	.
Primary oxalosis	*	*
Fabry's disease	*	*	.	*	.	.	.	0.2	.
Congenital nephrotic syndrome	35	24	*	.	.	0.1	.	.	.
Drash syndrome, mesangial sclerosis	*	*	*
Congenital obstructive uropathy	138	100	*	*	*	0.3	0.3	0.1	0.3
Renal hypoplasia, dysplasia	149	112	*	*	*	0.3	0.1	0.1	0.2
Prune belly syndrome	17	14	*	.	.	.	0.1	.	.
Neoplasms/tumors	483	381	26	14	*	1.0	1.2	1.7	0.7
Renal or urological neoplasms	148	109	10	*	*	0.3	0.5	0.4	0.3
Multiple myeloma	231	191	10	*	*	0.5	0.5	0.6	0.2
Light chain nephropathy	29	19	*	*	*	.	0.1	0.4	0.1
Amyloidosis	75	62	*	*	.	0.2	0.2	0.4	.
Miscellaneous conditions	1,065	721	73	23	18	1.8	3.5	2.7	2.0
Complication post bone marrow/other txp	23	17
Sickle cell disease/anemia or trait	12	*	*	.	.	.	0.2	0.1	.
AIDS nephropathy	264	121	35	*	*	0.3	1.7	0.8	0.5
Traumatic/surgical loss of kidney(s)	27	20	*	.	*	0.1	0.1	.	0.1
Hepatorenal syndrome	95	69	*	*	*	0.2	0.1	0.4	0.2
Tubular necrosis (no recovery)	315	233	14	*	*	0.6	0.7	0.9	0.2
Post-partum failure, other renal disorders	329	254	15	*	*	0.7	0.7	0.5	1.0
Etiology uncertain	1,763	1,327	74	31	25	3.4	3.5	3.7	2.8
Missing	394	142	*	*	*

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.14

Incidence of Reported ESRD, by Primary Diagnosis: Non-Hispanics, Row Percent

1996-2000 combined, by detailed primary diagnosis

	Total Patients	Percent Incident	Median Age	Percent Males	Percent White	Black	N Am	Asian	Tx 1st yr	Died 1st yr
All ESRD (reference)	384,415	100.0	64	53.4	61.1	33.0	1.4	3.7	5.5	23.5
Diabetes	157,691	42.2	64	48.4	59.2	33.7	2.4	4.1	3.3	23.2
Type 1, juvenile type	22,811	6.1	48	52.8	71.3	25.0	1.2	2.1	12.8	16.8
Type 2, adult-onset or unspecified type	134,880	36.1	65	47.7	57.2	35.2	2.6	4.4	1.7	24.3
Glomerulonephritis	36,777	9.8	55	61.4	64.8	27.0	1.2	6.0	12.2	13.3
Focal glomerulosclerosis, focal GN	9,231	2.5	49	61.4	56.3	39.3	0.8	3.0	13.8	10.0
Membranous nephropathy	1,894	0.5	59	66.7	68.6	27.5	0.7	2.7	11.2	12.9
Membranoproliferative GN, types 1&2	1,507	0.4	49	59.4	72.3	19.9	2.1	4.9	17.7	11.1
IgA nephropathy, Berger's disease	2,901	0.8	42	69.7	74.8	7.8	1.7	14.1	30.7	5.1
IgM nephropathy	294	0.1	47	67.0	73.8	10.2	1.0	13.9	27.6	5.1
Rapidly progressive GN	1,572	0.4	64	52.3	80.2	13.8	1.7	3.2	6.9	20.2
Goodpasture's Syndrome	493	0.1	56	47.9	90.1	7.3	1.2	1.2	6.7	19.7
Post infectious GN, SBE	338	0.1	55	69.8	76.6	15.7	3.6	3.3	9.5	18.3
Glomerulonephritis (GN)	17,413	4.7	60	61.0	63.6	26.9	1.2	7.2	8.3	15.8
Other proliferative GN	1,134	0.3	55	53.8	73.1	21.4	1.2	3.4	12.7	13.1
Secondary GN/vasculitis	8,889	2.4	48	33.3	58.4	36.3	1.1	3.5	7.1	19.5
Lupus erythematosus (SLE nephritis)	4,233	1.1	39	18.0	36.9	56.0	0.9	5.2	9.0	13.1
Polyarteritis	228	0.1	65	54.4	80.3	14.5	1.3	3.9	2.6	26.3
Wegener's granulomatosis	1,088	0.3	65	59.3	90.9	6.8	0.9	1.3	5.8	21.7
Henoch-Schonlein syndrome	148	.	32	54.1	83.1	10.1	2.0	4.7	25.0	8.1
Vasculitis and its derivatives	1,007	0.3	69	47.6	84.2	10.5	2.9	1.7	2.6	29.2
Scleroderma	780	0.2	57	23.6	76.0	20.9	1.2	1.7	2.3	38.3
Hemolytic uremic syndrome	736	0.2	46	34.4	77.2	20.7	0.4	1.2	9.9	18.9
Nephropathy from heroin /related abuse	249	0.1	45	71.9	26.9	71.5	0.4	1.2	2.0	15.7
Secondary GN, other	420	0.1	55	59.8	61.9	32.9	1.0	3.8	5.2	24.3
Interstitial nephritis/pyelonephritis	15,445	4.1	66	55.9	79.9	16.3	0.6	2.5	7.5	22.6
Chronic pyelonephritis, reflux neph.	2,197	0.6	46	39.7	86.4	9.6	0.9	2.1	22.6	11.4
Analgesic abuse	900	0.2	67	37.6	78.4	18.4	0.7	1.9	4.4	19.2
Nephropathy caused by other agents	2,214	0.6	62	58.3	79.2	18.5	0.4	1.4	6.1	28.1
Nephrolithiasis, obstruction, gouty	5,142	1.4	70	72.2	77.7	17.8	0.6	3.1	2.5	25.7
Nephrocalcinosis	281	0.1	67	49.8	81.9	13.9	0.4	2.8	8.5	19.2
Chronic interstitial nephritis	3,981	1.1	66	48.3	78.8	17.1	0.7	2.9	7.8	21.3
Acute interstitial nephritis	730	0.2	69	48.5	84.4	13.6	0.5	1.4	2.5	31.1
Hypertensive/large vessel disease	104,014	27.8	70	56.5	55.9	40.0	0.4	3.1	1.8	26.1
Hypertension (no primary renal disease)	91,350	24.4	69	56.2	50.8	44.8	0.5	3.4	1.9	24.7
Renal artery stenosis or occlusion	8,455	2.3	74	54.6	91.9	6.5	0.3	1.1	0.5	36.8
Cholesterol emboli, renal emboli	4,209	1.1	73	66.3	94.9	3.5	0.3	1.1	0.5	36.7
Cystic/hereditary/congenital diseases	12,751	3.4	50	56.9	81.0	14.9	0.5	2.5	25.1	6.5
Polycystic kidneys, adult (dominant)	9,032	2.4	54	53.7	82.0	14.3	0.3	2.5	20.5	6.7
Polycystic, infantile (recessive)	199	0.1	18	47.2	82.9	12.1	.	1.5	39.7	9.0
Medullary cystic, including nephronophthisis	201	0.1	26	48.3	83.6	10.4	1.0	3.5	43.8	3.0
Alport's, other hereditary/familial disease	950	0.3	37	65.8	86.3	9.8	0.8	2.1	33.5	2.6
Tuberous sclerosis	119	.	56	50.4	72.3	21.8	1.7	1.7	10.9	21.8
Cystinosis	54	.	16	40.7	85.2	11.1	1.9	1.9	50.0	7.4
Primary oxalosis	46	.	47	43.5	80.4	4.3	2.2	4.3	32.6	6.5
Fabry's disease	69	.	43	92.8	91.3	5.8	2.9	.	26.1	8.7
Congenital nephrotic syndrome	233	0.1	27	56.2	67.8	23.6	0.9	4.7	30.5	12.4
Drash syndrome, mesangial sclerosis	26	.	37	57.7	84.6	11.5	.	3.8	15.4	11.5
Congenital obstructive uropathy	1,037	0.3	24	74.7	75.7	19.0	0.8	2.8	35.8	7.7
Renal hypoplasia, dysplasia	682	0.2	13	58.9	72.0	22.3	1.3	2.1	43.4	4.1
Prune belly syndrome	103	.	12	97.1	68.9	28.2	.	1.0	38.8	5.8
Neoplasms/tumors	7,706	2.1	69	61.1	76.8	20.8	0.5	1.4	0.9	49.2
Renal or urological neoplasms	2,203	0.6	69	73.2	79.7	18.9	0.5	0.7	1.3	39.9
Multiple myeloma	3,924	1.0	69	55.8	73.5	23.4	0.4	2.0	.	57.3
Light chain nephropathy	503	0.1	71	61.2	80.5	17.7	0.2	1.2	1.4	41.6
Amyloidosis	1,076	0.3	67	55.3	81.0	16.4	0.7	0.9	3.1	42.2
Miscellaneous conditions	15,694	4.2	58	62.9	59.4	38.3	0.5	1.4	3.1	35.8
Complication post bone marrow/other txp	462	0.1	55	64.3	88.3	8.4	0.6	1.7	16.5	23.6
Sickle cell disease/anemia or trait	480	0.1	41	50.4	2.3	97.1	.	0.6	1.7	24.2
AIDS nephropathy	3,960	1.1	39	70.5	4.7	94.4	0.4	0.2	.	33.1
Traumatic/surgical loss of kidney(s)	458	0.1	68	68.1	80.6	17.5	0.2	1.3	2.8	26.4
Hepatorenal syndrome	649	0.2	54	67.3	78.1	16.3	2.5	2.5	11.6	67.3
Tubular necrosis (no recovery)	5,437	1.5	70	58.9	82.9	14.9	0.5	1.4	0.8	39.5
Post-partum failure, other renal disorders	4,248	1.1	67	60.8	78.4	18.1	0.5	2.4	6.6	34.1
Etiology uncertain	15,089	4.0	69	57.3	69.3	25.3	0.8	3.7	4.7	29.5
Missing	10,359	.	51	54.7	57.0	31.3	0.9	3.6	32.2	16.9

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 "." Zero values in this cell.

Table A.15
Incidence of Reported ESRD, by Primary Diagnosis: Non-Hispanics, Column Percent
 1996-2000 combined, by detailed primary diagnosis

	Total Patients	Counts				Percent			
		White	Black	N Am	Asian	White	Black	N Am	Asian
All ESRD (reference)	384,415	234,781	127,014	5,277	14,175	100.0	100.0	100.0	100.0
Diabetes	157,691	93,358	53,114	3,780	6,432	40.8	42.9	72.9	46.6
Type 1, juvenile type	22,811	16,259	5,697	283	482	7.1	4.6	5.5	3.5
Type 2, adult-onset or unspecified type	134,880	77,099	47,417	3,497	5,950	33.7	38.3	67.4	43.1
Glomerulonephritis	36,777	23,844	9,942	437	2,208	10.4	8.0	8.4	16.0
Focal glomerulosclerosis, focal GN	9,231	5,193	3,626	71	276	2.3	2.9	1.4	2.0
Membranous nephropathy	1,894	1,299	521	14	52	0.6	0.4	0.3	0.4
Membranoproliferative GN, types 1&2	1,507	1,090	300	31	74	0.5	0.2	0.6	0.5
IgA nephropathy, Berger's disease	2,901	2,171	227	49	408	0.9	0.2	0.9	3.0
IgM nephropathy	294	217	30	*	41	0.1	.	0.1	0.3
Rapidly progressive GN	1,572	1,261	217	27	51	0.6	0.2	0.5	0.4
Goodpasture's Syndrome	493	444	36	*	*	0.2	.	0.1	.
Post infectious GN, SBE	338	259	53	12	11	0.1	.	0.2	0.1
Glomerulonephritis (GN)	17,413	11,081	4,689	210	1,251	4.8	3.8	4.0	9.1
Other proliferative GN	1,134	829	243	14	38	0.4	0.2	0.3	0.3
Secondary GN/vasculitis	8,889	5,195	3,230	101	309	2.3	2.6	1.9	2.2
Lupus erythematosus (SLE nephritis)	4,233	1,564	2,371	39	221	0.7	1.9	0.8	1.6
Polyarteritis	228	183	33	*	*	0.1	.	0.1	0.1
Wegener's granulomatosis	1,088	989	74	10	14	0.4	0.1	0.2	0.1
Henoch-Schonlein syndrome	148	123	15	*	*	0.1	.	0.1	0.1
Vasculitis and its derivatives	1,007	848	106	29	17	0.4	0.1	0.6	0.1
Scleroderma	780	593	163	*	13	0.3	0.1	0.2	0.1
Hemolytic uremic syndrome	736	568	152	*	*	0.2	0.1	0.1	0.1
Nephropathy from heroin/related abuse	249	67	178	*	*	.	0.1	.	.
Secondary GN, other	420	260	138	*	16	0.1	0.1	0.1	0.1
Interstitial nephritis/pyelonephritis	15,445	12,338	2,520	99	387	5.4	2.0	1.9	2.8
Chronic pyelonephritis, reflux neph.	2,197	1,899	210	20	47	0.8	0.2	0.4	0.3
Analgesic abuse	900	706	166	*	17	0.3	0.1	0.1	0.1
Nephropathy caused by other agents	2,214	1,754	409	*	31	0.8	0.3	0.2	0.2
Nephrolithiasis, obstruction, gouty	5,142	3,997	917	32	157	1.7	0.7	0.6	1.1
Nephrocalcinosis	281	230	39	*	*	0.1	.	.	0.1
Chronic interstitial nephritis	3,981	3,136	680	27	117	1.4	0.5	0.5	0.8
Acute interstitial nephritis	730	616	99	*	10	0.3	0.1	0.1	0.1
Hypertensive/large vessel disease	104,014	58,138	41,641	456	3,265	25.4	33.6	8.8	23.7
Hypertension (no primary renal disease)	91,350	46,377	40,940	418	3,124	20.3	33.1	8.1	22.6
Renal artery stenosis or occlusion	8,455	7,766	552	24	95	3.4	0.4	0.5	0.7
Cholesterol emboli, renal emboli	4,209	3,995	149	14	46	1.7	0.1	0.3	0.3
Cystic/hereditary/congenital diseases	12,751	10,322	1,901	64	320	4.5	1.5	1.2	2.3
Polycystic kidneys, adult (dominant)	9,032	7,410	1,289	29	229	3.2	1.0	0.6	1.7
Polycystic, infantile (recessive)	199	165	24	.	*	0.1	.	.	.
Medullary cystic, including nephronphthisis	201	168	21	*	*	0.1	.	.	0.1
Alport's, other hereditary/familial disease	950	820	93	*	20	0.4	0.1	0.2	0.1
Tuberous sclerosis	119	86	26	*	*
Cystinosis	54	46	*	*	*
Primary oxalosis	46	37	*	*	*
Fabry's disease	69	63	*	*
Congenital nephrotic syndrome	233	158	55	*	11	0.1	.	.	0.1
Drash syndrome, mesangial sclerosis	26	22	*	.	*
Congenital obstructive uropathy	1,037	785	197	*	29	0.3	0.2	0.2	0.2
Renal hypoplasia, dysplasia	682	491	152	*	14	0.2	0.1	0.2	0.1
Prune belly syndrome	103	71	29	.	*
Neoplasms/tumors	7,706	5,915	1,602	37	109	2.6	1.3	0.7	0.8
Renal or urological neoplasms	2,203	1,755	416	12	15	0.8	0.3	0.2	0.1
Multiple myeloma	3,924	2,883	920	17	78	1.3	0.7	0.3	0.6
Light chain nephropathy	503	405	89	*	*	0.2	0.1	.	.
Amyloidosis	1,076	872	177	*	10	0.4	0.1	0.1	0.1
Miscellaneous conditions	15,694	9,317	6,010	85	217	4.1	4.9	1.6	1.6
Complication post bone marrow/other txp	462	408	39	*	*	0.2	.	0.1	0.1
Sickle cell disease/anemia or trait	480	11	466	.	*	.	0.4	.	.
AIDS nephropathy	3,960	185	3,738	17	*	0.1	3.0	0.3	.
Traumatic/surgical loss of kidney(s)	458	369	80	*	*	0.2	0.1	.	.
Hepatorenal syndrome	649	507	106	16	16	0.2	0.1	0.3	0.1
Tubular necrosis (no recovery)	5,437	4,506	812	25	76	2.0	0.7	0.5	0.6
Post-partum failure, other renal disorders	4,248	3,331	769	23	102	1.5	0.6	0.4	0.7
Etiology uncertain	15,089	10,452	3,811	128	556	4.6	3.1	2.5	4.0
Missing	10,359	5,902	3,243	90	372

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.16

Incident Counts of Reported ESRD Patients, by Diabetic Status & State/Territory: All Patients

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	1,043	1,141	1,124	1,267	1,378	1,485	1,651	1,587	1,695	1,809
Alaska	51	55	50	198	339	65	79	69	74	92
Arizona	817	1,003	1,021	1,092	1,195	1,294	1,387	1,533	1,655	1,714
Arkansas	508	526	567	693	732	723	823	769	823	890
California	6,055	6,178	6,627	7,644	7,977	8,579	9,196	9,915	10,462	11,288
Colorado	472	518	542	559	553	673	709	792	769	815
Connecticut	661	684	680	866	851	896	924	932	929	1,048
Delaware	176	202	187	223	232	224	227	237	269	284
District of Columbia	311	327	321	295	406	398	413	413	432	469
Florida	3,295	3,667	3,681	4,007	4,307	4,902	4,943	5,142	5,465	5,795
Georgia	1,700	1,901	1,875	2,179	2,283	2,477	2,485	2,661	2,928	3,242
Hawaii	268	287	321	401	387	382	423	443	475	524
Idaho	137	126	136	179	193	212	226	214	251	255
Illinois	2,674	2,748	3,093	3,421	3,513	3,656	3,802	4,101	4,326	4,401
Indiana	1,021	1,174	1,244	1,153	1,558	1,512	1,586	1,803	1,791	1,971
Iowa	456	526	519	585	538	606	610	668	786	725
Kansas	411	437	409	518	504	568	653	669	682	712
Kentucky	709	779	812	740	960	972	1,017	1,115	1,241	1,218
Louisiana	1,172	1,327	1,309	1,479	1,614	1,622	1,837	2,031	2,159	2,099
Maine	138	154	163	198	226	216	263	260	238	310
Maryland	1,197	1,282	1,333	1,356	1,776	1,882	1,905	2,063	2,118	2,238
Massachusetts	1,047	1,190	1,240	1,395	1,382	1,491	1,582	1,638	1,439	1,723
Michigan	1,860	2,106	2,217	2,501	2,577	2,914	2,927	3,144	3,230	3,392
Minnesota	703	760	781	952	842	927	1,003	1,053	1,056	1,126
Mississippi	654	745	776	950	911	1,021	1,081	1,134	1,190	1,156
Missouri	1,099	1,158	1,231	1,392	1,447	1,513	1,626	1,790	1,834	1,927
Montana	141	125	143	147	165	148	145	162	199	167
Nebraska	255	295	271	335	323	354	407	420	468	508
Nevada	243	243	279	352	354	376	399	463	556	566
New Hampshire	144	152	147	183	184	162	200	223	222	287
New Jersey	1,928	2,048	2,174	2,464	2,620	2,638	2,885	3,074	3,269	3,079
New Mexico	342	334	360	364	432	483	488	473	557	597
New York	3,622	4,061	4,282	5,124	5,091	5,546	5,907	6,164	6,409	6,634
North Carolina	1,629	1,798	1,938	2,185	2,122	2,407	2,609	2,788	2,788	3,164
North Dakota	100	124	124	152	117	138	141	137	144	168
Ohio	2,111	2,429	2,481	2,551	3,269	3,360	3,365	3,720	3,977	4,344
Oklahoma	551	654	708	747	785	820	947	1,046	1,042	1,120
Oregon	505	479	538	586	579	603	633	666	719	765
Pennsylvania	2,719	2,936	2,822	3,604	3,658	3,918	4,107	4,216	4,432	4,502
Rhode Island	203	205	231	262	233	275	265	294	280	330
South Carolina	967	1,046	1,083	1,332	1,242	1,374	1,456	1,588	1,649	1,639
South Dakota	99	113	128	143	184	194	199	198	220	242
Tennessee	1,147	1,217	1,180	1,454	1,493	1,554	1,710	1,784	1,943	1,941
Texas	3,741	4,185	4,303	4,739	4,999	5,516	5,831	6,235	6,637	7,102
Utah	194	199	263	244	267	268	265	348	352	342
Vermont	85	64	74	85	104	109	108	115	118	126
Virginia	1,447	1,575	1,562	1,671	1,960	2,104	2,335	2,324	2,443	2,363
Washington	743	774	811	940	963	1,004	1,045	1,100	1,237	1,338
West Virginia	359	385	402	446	501	539	609	643	645	733
Wisconsin	862	959	924	1,064	1,073	1,164	1,215	1,347	1,344	1,415
Wyoming	45	42	53	44	65	68	68	75	88	83
American Samoa	*	13	*	*	10	11	*	*	17	22
Guam	32	40	34	38	50	63	74	69	71	73
Puerto Rico	628	725	685	857	854	954	971	1,048	1,114	1,106
Saipan	*	*	*	*	12	13	17	23	15	20
Virgin Islands	17	24	17	24	33	34	44	42	35	30
Foreign	46	53	54	67	40	44	44	50	30	37
Unknown	570	820	1,282	5,018	411	80	36	43	87	126
All	54,122	59,127	61,627	73,480	72,874	77,531	81,911	87,062	91,424	96,192

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

Table A.16 (continued)

Incident Counts of Reported ESRD Patients, by Diabetic Status & State/Territory: All Patients

DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	311	382	365	460	532	583	714	660	762	779
Alaska	14	17	24	57	117	31	43	31	38	39
Arizona	378	479	480	515	613	633	722	787	845	902
Arkansas	183	174	179	219	280	305	319	302	333	359
California	2,301	2,366	2,406	3,033	3,345	3,726	4,252	4,520	4,770	5,211
Colorado	199	212	244	224	254	328	319	377	355	391
Connecticut	226	237	220	324	330	340	418	374	372	437
Delaware	59	55	60	71	78	81	84	95	117	127
District of Columbia	83	110	85	73	117	161	148	142	154	166
Florida	977	1,129	1,083	1,285	1,328	1,783	1,876	1,927	2,103	2,304
Georgia	535	644	611	754	896	1,064	1,020	1,119	1,222	1,338
Hawaii	141	146	180	226	227	232	246	257	259	312
Idaho	40	60	55	78	73	87	100	97	117	117
Illinois	841	831	883	1,159	1,320	1,425	1,450	1,566	1,770	1,734
Indiana	359	411	372	345	589	636	661	801	765	794
Iowa	146	187	193	214	230	256	248	275	316	297
Kansas	161	148	149	205	188	231	261	314	309	335
Kentucky	241	243	272	229	345	411	435	485	546	529
Louisiana	438	499	426	546	617	711	796	913	943	877
Maine	42	52	58	63	73	76	99	95	96	132
Maryland	421	470	431	460	575	719	788	830	841	812
Massachusetts	340	407	377	501	521	585	598	645	518	639
Michigan	729	825	782	976	1,059	1,292	1,295	1,403	1,402	1,486
Minnesota	260	272	281	340	329	351	383	395	383	411
Mississippi	225	261	263	331	364	443	441	499	524	486
Missouri	372	419	450	516	578	649	734	787	770	838
Montana	62	66	55	65	85	65	68	81	93	78
Nebraska	100	114	108	125	163	155	173	172	213	215
Nevada	87	79	92	123	158	131	179	208	253	252
New Hampshire	45	43	41	54	70	57	73	83	79	103
New Jersey	658	657	700	876	1,040	1,079	1,165	1,310	1,327	1,225
New Mexico	189	191	202	192	244	286	275	284	339	363
New York	1,206	1,349	1,341	1,648	1,888	2,213	2,368	2,424	2,563	2,659
North Carolina	581	629	692	849	857	1,022	1,129	1,256	1,199	1,359
North Dakota	38	60	49	64	52	50	60	66	43	64
Ohio	712	901	889	917	1,286	1,451	1,517	1,698	1,857	1,999
Oklahoma	242	310	307	333	383	382	455	552	538	549
Oregon	162	175	189	215	226	233	255	251	301	306
Pennsylvania	960	1,048	928	1,270	1,471	1,534	1,641	1,728	1,802	1,882
Rhode Island	52	66	69	81	84	107	105	120	100	102
South Carolina	346	370	367	486	477	587	594	725	727	707
South Dakota	52	57	60	62	95	91	91	86	119	104
Tennessee	356	423	395	502	593	615	681	704	774	829
Texas	1,566	1,732	1,881	2,133	2,388	2,721	3,007	3,162	3,335	3,649
Utah	83	84	111	113	144	129	129	157	161	163
Vermont	31	17	28	41	50	42	48	48	56	46
Virginia	459	516	523	605	649	805	970	986	1,011	997
Washington	284	318	308	349	382	408	456	464	519	569
West Virginia	125	158	137	167	203	236	279	277	321	381
Wisconsin	337	378	344	385	440	471	528	545	541	551
Wyoming	14	*	25	22	37	30	35	33	41	42
American Samoa	*	*	*	*	*	*	*	*	*	18
Guam	19	24	17	23	33	45	49	45	49	40
Puerto Rico	326	398	323	448	441	536	537	623	680	634
Saipan	*	*	*	*	10	*	13	17	10	14
Virgin Islands	*	*	*	*	17	19	21	18	20	16
Foreign	*	*	*	19	*	*	*	*	*	*
Unknown	91	162	254	736	107	*	.	*	*	*
All	19,222	21,390	21,379	26,123	29,062	32,661	35,358	37,831	39,718	41,772

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.16 (continued)

Incident Counts of Reported ESRD Patients, by Diabetic Status & State/Territory: All Patients

NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	732	759	759	807	846	902	937	927	933	1,030
Alaska	37	38	26	141	222	34	36	38	36	53
Arizona	439	524	541	577	582	661	665	746	810	812
Arkansas	325	352	388	474	452	418	504	467	490	531
California	3,754	3,812	4,221	4,611	4,632	4,853	4,944	5,395	5,692	6,077
Colorado	273	306	298	335	299	345	390	415	414	424
Connecticut	435	447	460	542	521	556	506	558	557	611
Delaware	117	147	127	152	154	143	143	142	152	157
District of Columbia	228	217	236	222	289	237	265	271	278	303
Florida	2,318	2,538	2,598	2,722	2,979	3,119	3,067	3,215	3,362	3,491
Georgia	1,165	1,257	1,264	1,425	1,387	1,413	1,465	1,542	1,706	1,904
Hawaii	127	141	141	175	160	150	177	186	216	212
Idaho	97	66	81	101	120	125	126	117	134	138
Illinois	1,833	1,917	2,210	2,262	2,193	2,231	2,352	2,535	2,556	2,667
Indiana	662	763	872	808	969	876	925	1,002	1,026	1,177
Iowa	310	339	326	371	308	350	362	393	470	428
Kansas	250	289	260	313	316	337	392	355	373	377
Kentucky	468	536	540	511	615	561	582	630	695	689
Louisiana	734	828	883	933	997	911	1,041	1,118	1,216	1,222
Maine	96	102	105	135	153	140	164	165	142	178
Maryland	776	812	902	896	1,201	1,163	1,117	1,233	1,277	1,426
Massachusetts	707	783	863	894	861	906	984	993	921	1,084
Michigan	1,131	1,281	1,435	1,525	1,518	1,622	1,632	1,741	1,828	1,906
Minnesota	443	488	500	612	513	576	620	658	673	715
Mississippi	429	484	513	619	547	578	640	635	666	670
Missouri	727	739	781	876	869	864	892	1,003	1,064	1,089
Montana	79	59	88	82	80	83	77	81	106	89
Nebraska	155	181	163	210	160	199	234	248	255	293
Nevada	156	164	187	229	196	245	220	255	303	314
New Hampshire	99	109	106	129	114	105	127	140	143	184
New Jersey	1,270	1,391	1,474	1,588	1,580	1,559	1,720	1,764	1,942	1,854
New Mexico	153	143	158	172	188	197	213	189	218	234
New York	2,416	2,712	2,941	3,476	3,203	3,333	3,539	3,740	3,846	3,975
North Carolina	1,048	1,169	1,246	1,336	1,265	1,385	1,480	1,532	1,589	1,805
North Dakota	62	64	75	88	65	88	81	71	101	104
Ohio	1,399	1,528	1,592	1,634	1,983	1,909	1,848	2,022	2,120	2,345
Oklahoma	309	344	401	414	402	438	492	494	504	571
Oregon	343	304	349	371	353	370	378	415	418	459
Pennsylvania	1,759	1,888	1,894	2,334	2,187	2,384	2,466	2,488	2,630	2,620
Rhode Island	151	139	162	181	149	168	160	174	180	228
South Carolina	621	676	716	846	765	787	862	863	922	932
South Dakota	47	56	68	81	89	103	108	112	101	138
Tennessee	791	794	785	952	900	939	1,029	1,080	1,169	1,112
Texas	2,175	2,453	2,422	2,606	2,611	2,795	2,824	3,073	3,302	3,453
Utah	111	115	152	131	123	139	136	191	191	179
Vermont	54	47	46	44	54	67	60	67	62	80
Virginia	988	1,059	1,039	1,066	1,311	1,299	1,365	1,338	1,432	1,366
Washington	459	456	503	591	581	596	589	636	718	769
West Virginia	234	227	265	279	298	303	330	366	324	352
Wisconsin	525	581	580	679	633	693	687	802	803	864
Wyoming	31	33	28	22	28	38	33	42	47	41
American Samoa	*	*	*	*	*	*	*	*	*	*
Guam	13	16	17	15	17	18	25	24	22	33
Puerto Rico	302	327	362	409	413	418	434	425	434	472
Saipan	*	*	*	*	*	*	*	*	*	*
Virgin Islands	12	18	11	18	16	15	23	24	15	14
Foreign	39	48	52	48	35	39	41	44	23	34
Unknown	479	658	1,028	4,282	304	78	36	41	85	125
All	34,900	37,737	40,248	47,357	43,812	44,870	46,553	49,231	51,706	54,420

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 *Values for cells with fewer than 10 patients are suppressed.

Table A.17

Incident Counts of Reported ESRD Patients, by Diabetic Status & State: U.S. Only, with Unknowns Dropped

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	1,042	1,140	1,121	1,264	1,376	1,484	1,650	1,583	1,690	1,800
Alaska	51	54	50	182	321	65	77	69	72	92
Arizona	813	999	1,011	1,075	1,177	1,269	1,365	1,503	1,616	1,661
Arkansas	508	526	565	693	731	722	819	765	815	878
California	5,975	6,078	6,446	7,444	7,630	8,094	8,716	9,684	10,157	10,798
Colorado	471	518	539	556	541	663	696	780	766	809
Connecticut	659	684	678	861	842	884	904	916	899	1,017
Delaware	176	202	186	222	232	221	223	234	267	282
District of Columbia	310	324	319	294	398	390	405	406	426	458
Florida	3,293	3,665	3,678	3,991	4,256	4,848	4,896	5,091	5,382	5,721
Georgia	1,699	1,895	1,875	2,172	2,271	2,459	2,474	2,641	2,898	3,190
Hawaii	266	284	314	390	373	354	408	432	457	503
Idaho	137	123	135	179	193	211	225	214	249	254
Illinois	2,671	2,743	3,079	3,390	3,456	3,606	3,742	4,031	4,302	4,308
Indiana	1,020	1,170	1,241	1,150	1,541	1,498	1,579	1,794	1,775	1,951
Iowa	456	526	519	583	534	603	602	664	785	724
Kansas	411	437	407	516	491	557	633	655	681	709
Kentucky	705	776	810	737	955	966	1,013	1,113	1,237	1,212
Louisiana	1,172	1,327	1,309	1,475	1,607	1,620	1,833	2,021	2,153	2,086
Maine	138	154	163	198	224	216	262	260	238	310
Maryland	1,196	1,281	1,333	1,351	1,754	1,853	1,881	2,033	2,089	2,202
Massachusetts	1,042	1,184	1,232	1,383	1,359	1,442	1,562	1,608	1,397	1,680
Michigan	1,859	2,102	2,216	2,487	2,569	2,908	2,901	3,130	3,214	3,367
Minnesota	702	760	777	947	835	921	994	1,044	1,051	1,108
Mississippi	652	744	776	941	910	1,018	1,079	1,134	1,190	1,149
Missouri	1,099	1,158	1,231	1,387	1,436	1,508	1,612	1,779	1,831	1,919
Montana	141	125	143	147	162	148	144	161	199	167
Nebraska	255	294	271	334	318	348	400	416	466	508
Nevada	242	243	279	349	350	371	388	458	544	540
New Hampshire	144	152	146	183	183	161	198	221	221	282
New Jersey	1,922	2,042	2,162	2,433	2,574	2,570	2,811	2,976	3,177	2,973
New Mexico	340	326	357	354	427	469	479	458	534	576
New York	3,603	4,032	4,245	4,960	4,851	5,309	5,651	5,894	6,121	6,266
North Carolina	1,627	1,797	1,935	2,178	2,111	2,399	2,596	2,764	2,771	3,128
North Dakota	100	124	124	150	117	137	141	137	143	165
Ohio	2,108	2,421	2,475	2,542	3,246	3,326	3,337	3,690	3,951	4,306
Oklahoma	551	654	706	743	778	815	933	1,034	1,027	1,094
Oregon	505	478	537	584	574	598	631	663	714	760
Pennsylvania	2,712	2,926	2,817	3,582	3,616	3,879	4,070	4,178	4,376	4,431
Rhode Island	201	204	231	260	229	268	264	291	274	322
South Carolina	967	1,046	1,083	1,330	1,235	1,370	1,453	1,586	1,643	1,636
South Dakota	99	112	128	143	184	194	199	198	220	241
Tennessee	1,147	1,217	1,178	1,446	1,485	1,551	1,707	1,782	1,932	1,932
Texas	3,717	4,174	4,289	4,695	4,796	5,272	5,644	6,094	6,513	6,802
Utah	194	199	260	244	262	264	260	342	351	337
Vermont	85	64	73	85	103	109	108	115	118	126
Virginia	1,445	1,573	1,557	1,666	1,934	2,078	2,307	2,297	2,418	2,319
Washington	742	773	807	936	938	995	1,039	1,088	1,231	1,332
West Virginia	358	385	402	446	499	536	609	642	643	730
Wisconsin	860	958	922	1,062	1,069	1,161	1,213	1,340	1,342	1,396
Wyoming	45	41	52	44	65	67	67	75	88	78
All	52,633	57,214	59,189	66,764	70,118	74,775	79,200	84,484	88,654	92,635

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

Table A.17 (continued)

Incident Counts of Reported ESRD Patients, by Diabetic Status & State: U.S. Only, with Unknowns Dropped

DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	311	382	365	460	531	582	713	660	762	775
Alaska	14	16	24	55	112	31	43	31	36	39
Arizona	376	477	475	504	607	620	709	776	826	875
Arkansas	183	174	179	219	279	305	318	299	329	357
California	2,281	2,331	2,354	2,958	3,189	3,484	4,008	4,420	4,646	4,995
Colorado	199	212	243	224	246	323	310	371	352	389
Connecticut	226	237	220	321	327	335	408	368	363	420
Delaware	59	55	59	71	78	79	81	94	116	126
District of Columbia	83	110	85	73	116	159	146	140	153	163
Florida	977	1,129	1,083	1,280	1,315	1,762	1,855	1,906	2,069	2,268
Georgia	535	641	611	752	895	1,060	1,016	1,110	1,215	1,321
Hawaii	140	146	176	219	217	215	239	252	254	300
Idaho	40	59	54	78	73	87	99	97	115	116
Illinois	840	831	877	1,153	1,295	1,394	1,416	1,531	1,758	1,701
Indiana	359	411	372	345	586	629	657	796	756	780
Iowa	146	187	193	214	230	254	243	273	316	296
Kansas	161	148	149	204	180	222	250	308	309	333
Kentucky	240	243	272	228	345	411	433	484	545	528
Louisiana	438	499	426	545	615	710	795	909	943	876
Maine	42	52	58	63	72	76	99	95	96	132
Maryland	421	470	431	458	566	715	782	822	830	801
Massachusetts	340	407	377	499	510	565	586	635	502	623
Michigan	729	824	782	973	1,055	1,289	1,287	1,402	1,396	1,477
Minnesota	260	272	280	339	327	350	381	394	380	402
Mississippi	225	261	263	329	364	443	441	499	524	485
Missouri	372	419	450	514	577	647	731	784	769	835
Montana	62	66	55	65	84	65	67	80	93	78
Nebraska	100	114	108	124	160	150	168	169	212	215
Nevada	87	79	92	122	156	129	172	206	249	246
New Hampshire	45	43	41	54	69	57	73	83	79	101
New Jersey	657	654	698	871	1,023	1,044	1,133	1,264	1,276	1,183
New Mexico	188	186	201	187	242	284	271	278	326	354
New York	1,204	1,346	1,333	1,608	1,783	2,117	2,242	2,315	2,429	2,495
North Carolina	581	629	692	849	856	1,019	1,126	1,250	1,195	1,349
North Dakota	38	60	49	62	52	49	60	66	42	64
Ohio	711	898	886	916	1,280	1,442	1,501	1,686	1,843	1,985
Oklahoma	242	310	306	332	380	380	446	542	532	537
Oregon	162	175	188	215	226	233	253	251	300	305
Pennsylvania	960	1,047	928	1,269	1,459	1,518	1,625	1,710	1,778	1,852
Rhode Island	52	66	69	81	82	104	105	119	97	99
South Carolina	346	370	367	486	476	587	594	725	725	707
South Dakota	52	56	60	62	95	91	91	86	119	104
Tennessee	356	423	395	501	591	614	680	703	771	828
Texas	1,560	1,729	1,876	2,120	2,284	2,595	2,913	3,091	3,267	3,499
Utah	83	84	111	113	142	128	127	155	161	162
Vermont	31	17	28	41	49	42	48	48	56	46
Virginia	459	516	522	605	647	801	961	983	1,008	984
Washington	283	318	307	349	373	403	452	461	518	567
West Virginia	125	158	137	167	203	236	279	277	321	379
Wisconsin	337	378	344	385	437	469	527	541	541	549
Wyoming	14	*	25	22	37	29	34	33	41	41
All	18,732	20,724	20,676	24,684	27,893	31,333	33,994	36,578	38,339	40,142

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

*Values for cells with fewer than 10 patients are suppressed.

Table A.17 (continued)

Incident Counts of Reported ESRD Patients, by Diabetic Status & State: U.S. Only, with Unknowns Dropped

NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	731	758	756	804	845	902	937	923	928	1,025
Alaska	37	38	26	127	209	34	34	38	36	53
Arizona	437	522	536	571	570	649	656	727	790	786
Arkansas	325	352	386	474	452	417	501	466	486	521
California	3,694	3,747	4,092	4,486	4,441	4,610	4,708	5,264	5,511	5,803
Colorado	272	306	296	332	295	340	386	409	414	420
Connecticut	433	447	458	540	515	549	496	548	536	597
Delaware	117	147	127	151	154	142	142	140	151	156
District of Columbia	227	214	234	221	282	231	259	266	273	295
Florida	2,316	2,536	2,595	2,711	2,941	3,086	3,041	3,185	3,313	3,453
Georgia	1,164	1,254	1,264	1,420	1,376	1,399	1,458	1,531	1,683	1,869
Hawaii	126	138	138	171	156	139	169	180	203	203
Idaho	97	64	81	101	120	124	126	117	134	138
Illinois	1,831	1,912	2,202	2,237	2,161	2,212	2,326	2,500	2,544	2,607
Indiana	661	759	869	805	955	869	922	998	1,019	1,171
Iowa	310	339	326	369	304	349	359	391	469	428
Kansas	250	289	258	312	311	335	383	347	372	376
Kentucky	465	533	538	509	610	555	580	629	692	684
Louisiana	734	828	883	930	992	910	1,038	1,112	1,210	1,210
Maine	96	102	105	135	152	140	163	165	142	178
Maryland	775	811	902	893	1,188	1,138	1,099	1,211	1,259	1,401
Massachusetts	702	777	855	884	849	877	976	973	895	1,057
Michigan	1,130	1,278	1,434	1,514	1,514	1,619	1,614	1,728	1,818	1,890
Minnesota	442	488	497	608	508	571	613	650	671	706
Mississippi	427	483	513	612	546	575	638	635	666	664
Missouri	727	739	781	873	859	861	881	995	1,062	1,084
Montana	79	59	88	82	78	83	77	81	106	89
Nebraska	155	180	163	210	158	198	232	247	254	293
Nevada	155	164	187	227	194	242	216	252	295	294
New Hampshire	99	109	105	129	114	104	125	138	142	181
New Jersey	1,265	1,388	1,464	1,562	1,551	1,526	1,678	1,712	1,901	1,790
New Mexico	152	140	156	167	185	185	208	180	208	222
New York	2,399	2,686	2,912	3,352	3,068	3,192	3,409	3,579	3,692	3,771
North Carolina	1,046	1,168	1,243	1,329	1,255	1,380	1,470	1,514	1,576	1,779
North Dakota	62	64	75	88	65	88	81	71	101	101
Ohio	1,397	1,523	1,589	1,626	1,966	1,884	1,836	2,004	2,108	2,321
Oklahoma	309	344	400	411	398	435	487	492	495	557
Oregon	343	303	349	369	348	365	378	412	414	455
Pennsylvania	1,752	1,879	1,889	2,313	2,157	2,361	2,445	2,468	2,598	2,579
Rhode Island	149	138	162	179	147	164	159	172	177	223
South Carolina	621	676	716	844	759	783	859	861	918	929
South Dakota	47	56	68	81	89	103	108	112	101	137
Tennessee	791	794	783	945	894	937	1,027	1,079	1,161	1,104
Texas	2,157	2,445	2,413	2,575	2,512	2,677	2,731	3,003	3,246	3,303
Utah	111	115	149	131	120	136	133	187	190	175
Vermont	54	47	45	44	54	67	60	67	62	80
Virginia	986	1,057	1,035	1,061	1,287	1,277	1,346	1,314	1,410	1,335
Washington	459	455	500	587	565	592	587	627	713	765
West Virginia	233	227	265	279	296	300	330	365	322	351
Wisconsin	523	580	578	677	632	692	686	799	801	847
Wyoming	31	32	27	22	28	38	33	42	47	37
All	33,901	36,490	38,513	42,080	42,225	43,442	45,206	47,906	50,315	52,493

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

Table A.18
Incident Rates of Reported ESRD, by Diabetic Status & State
per million population, adjusted for age, gender, & race

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	202	223	208	247	258	282	297	295	296	319
Alaska	195	179	198	675	1,162	218	281	201	169	259
Arizona	246	287	276	273	289	309	317	339	342	346
Arkansas	200	209	217	258	288	272	309	279	299	306
California	242	240	248	283	285	297	314	341	344	361
Colorado	186	195	195	197	196	220	233	250	237	250
Connecticut	224	233	221	287	275	287	286	292	282	319
Delaware	256	293	243	285	294	275	273	280	305	319
District of Columbia	172	217	196	145	237	223	199	228	245	301
Florida	222	242	240	249	261	299	280	288	295	308
Georgia	222	241	233	264	338	369	277	293	317	341
Hawaii	160	173	216	213	175	177	201	156	201	195
Idaho	189	270	381	331	202	284	337	209	247	207
Illinois	234	255	263	287	288	299	307	326	347	345
Indiana	207	234	253	232	300	297	297	337	330	356
Iowa	234	253	252	309	260	336	264	310	338	315
Kansas	204	208	204	249	240	273	294	306	307	311
Kentucky	217	252	242	218	295	283	288	315	344	331
Louisiana	244	263	257	283	298	291	332	353	396	379
Maine	159	403	142	433	416	340	221	287	206	337
Maryland	215	226	226	225	282	293	300	314	334	332
Massachusetts	200	234	230	269	266	273	283	294	245	290
Michigan	202	225	235	269	268	297	294	314	318	330
Minnesota	225	231	268	315	283	284	284	298	305	302
Mississippi	194	210	218	256	266	270	288	293	322	308
Missouri	217	232	252	276	281	303	307	333	341	350
Montana	301	146	138	298	371	127	157	272	339	145
Nebraska	212	216	246	288	229	281	276	309	350	351
Nevada	223	210	234	288	269	248	251	285	327	307
New Hampshire	218	228	175	229	216	237	169	264	170	250
New Jersey	241	253	263	294	308	304	327	340	359	332
New Mexico	237	217	210	240	266	271	288	242	292	303
New York	192	211	219	253	247	269	285	293	301	304
North Carolina	205	217	230	253	284	314	292	298	291	328
North Dakota	129	175	1,099	455	520	164	312	163	176	330
Ohio	202	231	230	229	296	304	300	327	349	372
Oklahoma	182	206	236	234	244	249	287	307	301	308
Oregon	249	204	245	264	247	253	218	297	282	274
Pennsylvania	227	243	232	299	299	312	323	329	346	344
Rhode Island	228	231	259	319	281	332	302	324	313	349
South Carolina	217	239	231	282	377	442	294	302	311	301
South Dakota	453	360	124	158	214	235	347	337	198	262
Tennessee	231	242	221	269	273	281	302	311	327	328
Texas	254	276	278	298	295	319	332	362	365	372
Utah	173	201	265	205	229	270	200	275	265	261
Vermont	625	221	342	133	456	322	364	354	201	220
Virginia	217	232	226	234	268	284	309	303	313	299
Washington	199	219	216	234	226	239	241	246	259	293
West Virginia	236	239	260	297	331	332	348	361	363	402
Wisconsin	225	251	249	262	272	285	286	315	317	329
Wyoming	306	135	186	137	188	230	202	228	263	192
All	219	235	239	266	275	289	300	315	325	334

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

Table A.18 (continued)

Incident Rates of Reported ESRD, by Diabetic Status & State

per million population, adjusted for age, gender, & race

DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	56	74	65	89	97	110	126	112	128	134
Alaska	41	49	113	235	337	98	180	104	67	118
Arizona	103	128	120	119	142	138	157	160	163	170
Arkansas	71	72	71	82	111	113	116	109	123	125
California	92	92	91	113	119	128	145	156	157	168
Colorado	77	78	82	79	88	110	98	117	108	117
Connecticut	78	84	72	111	109	111	134	120	117	132
Delaware	79	79	77	92	98	100	98	110	131	141
District of Columbia	36	64	32	25	69	92	73	60	68	91
Florida	68	78	73	82	83	111	108	111	114	123
Georgia	73	81	76	92	132	158	113	120	132	139
Hawaii	39	53	68	109	87	92	87	83	92	91
Idaho	35	54	213	67	59	129	154	95	82	89
Illinois	73	76	74	98	108	116	116	124	142	137
Indiana	71	83	78	70	112	123	124	149	141	140
Iowa	78	79	97	116	126	153	127	153	145	138
Kansas	84	71	77	101	91	107	121	144	143	152
Kentucky	74	84	83	68	106	119	122	136	154	143
Louisiana	84	95	85	99	113	123	138	155	173	150
Maine	74	191	40	110	155	122	93	155	63	218
Maryland	73	82	73	77	92	112	122	126	134	122
Massachusetts	66	81	71	100	104	107	108	126	93	109
Michigan	78	87	83	103	109	132	131	140	139	144
Minnesota	81	81	105	105	110	113	119	117	116	119
Mississippi	69	76	68	92	112	115	119	133	141	129
Missouri	75	88	87	103	115	128	140	147	144	154
Montana	164	58	50	89	187	49	50	105	236	58
Nebraska	90	90	107	105	128	115	122	135	171	156
Nevada	71	63	73	95	119	77	109	128	144	139
New Hampshire	41	54	71	66	100	59	59	130	59	89
New Jersey	81	80	84	106	123	123	132	144	144	132
New Mexico	108	101	101	109	128	151	152	128	168	162
New York	63	69	68	82	91	106	113	115	120	120
North Carolina	69	74	79	96	113	128	124	129	123	137
North Dakota	49	75	685	288	285	56	207	75	43	164
Ohio	66	84	83	81	113	130	135	148	160	169
Oklahoma	75	90	92	93	109	112	122	148	143	140
Oregon	76	75	91	104	98	108	90	101	121	104
Pennsylvania	79	87	74	104	122	121	127	134	138	141
Rhode Island	59	81	73	109	105	141	116	141	117	124
South Carolina	81	80	79	106	136	170	115	136	138	125
South Dakota	328	265	51	51	99	77	126	159	93	71
Tennessee	74	87	74	95	109	110	120	120	132	140
Texas	106	114	121	134	141	157	171	183	183	191
Utah	72	76	132	90	146	120	111	166	128	131
Vermont	151	145	242	64	156	126	149	83	86	102
Virginia	65	75	74	84	89	107	127	128	128	127
Washington	85	101	92	84	96	98	110	105	112	127
West Virginia	86	92	85	102	138	148	150	153	192	201
Wisconsin	88	90	90	91	110	120	129	131	136	132
Wyoming	29	*	46	72	70	53	124	85	91	70
All	78	85	83	98	109	121	129	137	141	145

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

*Values for cells with fewer than 10 patients are suppressed.

Table A.18 (continued)

Incident Rates of Reported ESRD, by Diabetic Status & State*per million population, adjusted for age, gender, & race*

NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	146	149	142	158	161	172	171	183	168	184
Alaska	155	130	85	440	825	120	101	97	102	141
Arizona	143	158	156	154	148	171	160	179	179	176
Arkansas	129	137	146	176	177	159	193	169	176	181
California	150	148	157	170	166	168	169	185	186	193
Colorado	109	117	113	119	108	110	136	133	129	133
Connecticut	146	149	149	175	166	175	152	172	165	187
Delaware	177	214	166	192	195	175	174	169	175	178
District of Columbia	136	153	164	120	168	131	125	169	177	209
Florida	154	164	167	166	178	188	171	177	181	185
Georgia	149	159	157	172	206	211	164	172	185	201
Hawaii	121	120	148	104	88	84	114	72	109	104
Idaho	154	217	168	264	143	155	183	114	165	119
Illinois	161	179	189	190	181	183	190	203	204	208
Indiana	136	151	175	162	188	174	173	189	189	216
Iowa	156	174	154	193	135	183	137	157	193	177
Kansas	120	138	128	149	149	166	173	161	164	159
Kentucky	143	167	159	149	189	164	166	179	189	188
Louisiana	160	168	172	184	185	168	194	198	223	229
Maine	85	212	102	322	261	218	128	132	143	119
Maryland	141	144	153	148	190	181	178	189	200	210
Massachusetts	135	152	159	169	162	166	175	169	152	181
Michigan	124	138	153	167	158	165	163	174	180	186
Minnesota	144	150	163	210	173	172	165	181	189	184
Mississippi	125	134	150	165	154	156	169	160	181	179
Missouri	143	144	165	173	166	175	167	186	197	196
Montana	137	88	87	209	184	78	107	167	103	87
Nebraska	122	125	139	183	101	166	154	175	179	196
Nevada	152	147	160	193	150	171	142	158	183	168
New Hampshire	177	174	103	164	116	178	109	133	111	161
New Jersey	160	173	179	188	186	181	195	196	215	200
New Mexico	129	115	108	131	138	120	137	113	124	141
New York	128	141	151	171	156	163	172	178	182	184
North Carolina	136	142	151	156	172	186	169	169	169	192
North Dakota	80	99	414	167	235	108	106	88	133	166
Ohio	136	147	147	148	183	175	165	179	189	202
Oklahoma	107	116	145	141	135	138	164	159	158	168
Oregon	173	130	155	160	149	146	128	197	160	170
Pennsylvania	148	156	157	194	178	191	196	195	207	203
Rhode Island	169	150	186	211	176	191	186	183	197	225
South Carolina	136	159	153	175	241	272	179	166	173	176
South Dakota	126	96	73	107	116	158	221	178	104	191
Tennessee	157	155	147	175	165	170	182	192	195	188
Texas	148	162	157	164	154	162	161	178	183	180
Utah	101	125	134	115	83	150	89	109	136	130
Vermont	475	76	100	70	299	195	215	272	114	118
Virginia	152	156	152	150	179	176	182	175	185	171
Washington	115	118	124	150	130	141	131	141	148	166
West Virginia	150	147	175	194	194	185	198	208	172	201
Wisconsin	137	161	159	171	162	166	156	184	181	196
Wyoming	277	120	140	65	118	178	78	143	172	122
All	142	150	156	168	166	168	171	179	185	189

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated properly.

Table A.19
Incident Counts of Reported ESRD Patients, by Diabetic Status & ESRD Network: All Patients

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	2,312	2,489	2,608	3,141	3,008	3,155	3,351	3,470	3,207	3,820
2 NY	3,676	4,125	4,357	6,171	5,186	5,553	5,910	6,157	6,401	6,697
3 NJ, PR, VI	2,646	2,909	3,080	3,746	3,538	3,622	3,898	4,158	4,411	4,210
4 DE, PA	2,901	3,165	3,020	4,177	3,782	4,156	4,332	4,446	4,693	4,776
5 MD, DC, VA, WV	3,331	3,578	3,618	3,856	4,655	4,926	5,265	5,456	5,640	5,797
6 NC, SC, GA	4,308	4,757	4,916	5,989	5,678	6,263	6,547	7,036	7,360	8,028
7 FL	3,302	3,672	3,694	4,027	4,313	4,914	4,949	5,151	5,476	5,798
8 AL, MS, TN	2,860	3,134	3,121	4,038	3,812	4,061	4,445	4,502	4,827	4,911
9 IN, KY, OH	3,853	4,399	4,542	4,477	5,821	5,834	5,962	6,626	6,995	7,519
10 IL	2,729	2,820	3,197	3,858	3,576	3,658	3,800	4,096	4,324	4,396
11 MI, MN, ND, SD, WI	3,638	4,077	4,212	5,273	4,904	5,348	5,492	5,887	6,000	6,344
12 IA, KS, MO, NE	2,229	2,426	2,441	3,051	2,833	3,043	3,295	3,551	3,789	3,872
13 AR, LA, OK	2,235	2,515	2,590	3,016	3,155	3,168	3,608	3,848	4,022	4,107
14 TX	3,759	4,225	4,412	4,776	5,054	5,524	5,836	6,240	6,645	7,105
15 AZ, CO, NV, NM, UT, WY	2,151	2,402	2,642	2,809	2,906	3,160	3,320	3,683	3,976	4,118
16 AK, ID, MT, OR, WA	1,581	1,552	1,666	1,961	1,969	2,036	2,130	2,208	2,480	2,616
17 N. CA, HI, GUAM, AS	2,618	2,714	2,944	3,421	3,397	3,606	3,823	4,072	4,289	4,672
18 S. CA	3,914	4,087	4,463	5,504	5,221	5,454	5,808	6,383	6,738	7,225
Unknown	79	81	104	189	66	50	140	92	151	181
All	54,122	59,127	61,627	73,480	72,874	77,531	81,911	87,062	91,424	96,192
DIABETIC										
1 CT, MA, ME, NH, RI, VT	738	824	800	1,080	1,135	1,207	1,341	1,366	1,221	1,458
2 NY	1,213	1,357	1,347	1,730	1,905	2,215	2,368	2,424	2,564	2,660
3 NJ, PR, VI	991	1,061	1,030	1,369	1,509	1,633	1,723	1,951	2,027	1,875
4 DE, PA	1,018	1,107	986	1,350	1,490	1,614	1,725	1,823	1,919	2,011
5 MD, DC, VA, WV	1,091	1,257	1,175	1,303	1,549	1,922	2,185	2,237	2,328	2,356
6 NC, SC, GA	1,463	1,647	1,676	2,127	2,245	2,673	2,743	3,100	3,148	3,403
7 FL	979	1,129	1,084	1,279	1,325	1,783	1,876	1,928	2,104	2,303
8 AL, MS, TN	892	1,068	1,022	1,328	1,501	1,641	1,835	1,863	2,061	2,098
9 IN, KY, OH	1,315	1,557	1,538	1,508	2,235	2,495	2,614	2,982	3,168	3,319
10 IL	844	837	888	1,186	1,340	1,428	1,449	1,569	1,768	1,734
11 MI, MN, ND, SD, WI	1,419	1,593	1,524	1,875	2,000	2,261	2,357	2,496	2,489	2,617
12 IA, KS, MO, NE	779	870	906	1,099	1,164	1,292	1,416	1,549	1,611	1,686
13 AR, LA, OK	863	986	915	1,130	1,294	1,398	1,570	1,768	1,814	1,786
14 TX	1,566	1,741	1,923	2,147	2,407	2,723	3,009	3,164	3,338	3,650
15 AZ, CO, NV, NM, UT, WY	967	1,083	1,197	1,267	1,471	1,535	1,660	1,847	1,994	2,117
16 AK, ID, MT, OR, WA	566	637	624	743	808	825	923	923	1,069	1,110
17 N. CA, HI, GUAM, AS	971	1,053	1,139	1,432	1,501	1,656	1,819	1,909	1,931	2,178
18 S. CA	1,535	1,570	1,599	2,158	2,182	2,359	2,711	2,932	3,164	3,411
Unknown	12	13	*	12	*	*	34	.	.	.
All	19,222	21,390	21,379	26,123	29,062	32,661	35,358	37,831	39,718	41,772
NON-DIABETIC										
1 CT, MA, ME, NH, RI, VT	1,574	1,665	1,808	2,061	1,873	1,948	2,010	2,104	1,986	2,362
2 NY	2,463	2,768	3,010	4,441	3,281	3,338	3,542	3,733	3,837	4,037
3 NJ, PR, VI	1,655	1,848	2,050	2,377	2,029	1,989	2,175	2,207	2,384	2,335
4 DE, PA	1,883	2,058	2,034	2,827	2,292	2,542	2,607	2,623	2,774	2,765
5 MD, DC, VA, WV	2,240	2,321	2,443	2,553	3,106	3,004	3,080	3,219	3,312	3,441
6 NC, SC, GA	2,845	3,110	3,240	3,862	3,433	3,590	3,804	3,936	4,212	4,625
7 FL	2,323	2,543	2,610	2,748	2,988	3,131	3,073	3,223	3,372	3,495
8 AL, MS, TN	1,968	2,066	2,099	2,710	2,311	2,420	2,610	2,639	2,766	2,813
9 IN, KY, OH	2,538	2,842	3,004	2,969	3,586	3,339	3,348	3,644	3,827	4,200
10 IL	1,885	1,983	2,309	2,672	2,236	2,230	2,351	2,527	2,556	2,662
11 MI, MN, ND, SD, WI	2,219	2,484	2,688	3,398	2,904	3,087	3,135	3,391	3,511	3,727
12 IA, KS, MO, NE	1,450	1,556	1,535	1,952	1,669	1,751	1,879	2,002	2,178	2,186
13 AR, LA, OK	1,372	1,529	1,675	1,886	1,861	1,770	2,038	2,080	2,208	2,321
14 TX	2,193	2,484	2,489	2,629	2,647	2,801	2,827	3,076	3,307	3,455
15 AZ, CO, NV, NM, UT, WY	1,184	1,319	1,445	1,542	1,435	1,625	1,660	1,836	1,982	2,001
16 AK, ID, MT, OR, WA	1,015	915	1,042	1,218	1,161	1,211	1,207	1,285	1,411	1,506
17 N. CA, HI, GUAM, AS	1,647	1,661	1,805	1,989	1,896	1,950	2,004	2,163	2,358	2,494
18 S. CA	2,379	2,517	2,864	3,346	3,039	3,095	3,097	3,451	3,574	3,814
Unknown	67	68	98	177	65	49	106	92	151	181
All	34,900	37,737	40,248	47,357	43,812	44,870	46,553	49,231	51,706	54,420

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule.
 *Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table A.20

Incident Counts of Reported ESRD Patients: U.S. Only, with Unknowns Dropped

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	2,266	2,440	2,522	2,966	2,957	3,080	3,295	3,412	3,126	3,728
2 NY	3,601	4,040	4,244	5,051	4,905	5,309	5,649	5,882	6,109	6,251
3 NJ	1,923	2,038	2,161	2,438	2,594	2,562	2,808	2,971	3,171	2,969
4 DE, PA	2,886	3,130	3,000	3,772	3,725	4,105	4,290	4,405	4,632	4,700
5 MD, DC, VA, WV	3,307	3,552	3,605	3,738	4,586	4,855	5,202	5,381	5,570	5,700
6 NC, SC, GA	4,291	4,736	4,891	5,679	5,626	6,231	6,520	6,988	7,305	7,938
7 FL	3,292	3,663	3,676	3,960	4,250	4,849	4,896	5,089	5,381	5,717
8 AL, MS, TN	2,842	3,100	3,076	3,658	3,781	4,052	4,435	4,496	4,809	4,885
9 IN, KY, OH	3,829	4,367	4,519	4,426	5,753	5,777	5,921	6,583	6,946	7,454
10 IL	2,668	2,745	3,085	3,436	3,483	3,603	3,736	4,023	4,295	4,302
11 MI, MN, ND, SD, WI	3,620	4,055	4,167	4,815	4,810	5,327	5,449	5,851	5,972	6,276
12 IA, KS, MO, NE	2,222	2,415	2,428	2,816	2,788	3,018	3,246	3,516	3,761	3,859
13 AR, LA, OK	2,230	2,507	2,578	2,924	3,129	3,155	3,584	3,819	3,993	4,054
14 TX	3,717	4,173	4,287	4,610	4,830	5,269	5,641	6,092	6,510	6,795
15 AZ, CO, NV, NM, UT, WY	2,103	2,325	2,499	2,646	2,849	3,100	3,256	3,613	3,896	3,999
16 AK, ID, MT, OR, WA	1,578	1,543	1,658	1,912	1,927	2,018	2,115	2,192	2,464	2,603
17 N. CA, HI	2,488	2,536	2,701	3,077	3,174	3,302	3,572	3,876	4,054	4,400
18 S. CA	3,745	3,821	4,052	4,781	4,906	5,129	5,468	6,230	6,543	6,871
All	52,608	57,186	59,149	66,705	70,073	74,741	79,083	84,419	88,537	92,501
DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	735	822	795	1,058	1,113	1,179	1,319	1,348	1,193	1,421
2 NY	1,204	1,348	1,334	1,619	1,787	2,118	2,242	2,315	2,429	2,495
3 NJ	658	654	699	873	1,032	1,043	1,133	1,264	1,276	1,183
4 DE, PA	1,018	1,103	985	1,329	1,477	1,596	1,706	1,804	1,894	1,980
5 MD, DC, VA, WV	1,088	1,253	1,175	1,300	1,535	1,912	2,168	2,222	2,312	2,327
6 NC, SC, GA	1,462	1,640	1,671	2,092	2,230	2,666	2,736	3,085	3,135	3,377
7 FL	977	1,129	1,083	1,270	1,313	1,762	1,855	1,906	2,069	2,267
8 AL, MS, TN	892	1,065	1,022	1,293	1,491	1,639	1,833	1,862	2,058	2,091
9 IN, KY, OH	1,311	1,550	1,532	1,500	2,217	2,479	2,592	2,964	3,144	3,290
10 IL	840	830	879	1,164	1,311	1,396	1,415	1,533	1,756	1,701
11 MI, MN, ND, SD, WI	1,416	1,589	1,516	1,828	1,984	2,254	2,346	2,490	2,479	2,596
12 IA, KS, MO, NE	779	868	901	1,052	1,146	1,274	1,392	1,534	1,608	1,680
13 AR, LA, OK	863	983	911	1,100	1,282	1,395	1,559	1,750	1,804	1,771
14 TX	1,559	1,729	1,876	2,091	2,300	2,595	2,914	3,092	3,268	3,498
15 AZ, CO, NV, NM, UT, WY	947	1,048	1,149	1,184	1,444	1,511	1,623	1,820	1,955	2,069
16 AK, ID, MT, OR, WA	563	634	622	728	793	820	914	919	1,062	1,106
17 N. CA, HI	923	988	1,049	1,288	1,383	1,489	1,673	1,799	1,815	2,039
18 S. CA	1,496	1,488	1,477	1,907	2,055	2,204	2,546	2,871	3,082	3,251
All	18,731	20,721	20,676	24,676	27,893	31,332	33,966	36,578	38,339	40,142
NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	1,531	1,618	1,727	1,908	1,844	1,901	1,976	2,064	1,933	2,307
2 NY	2,397	2,692	2,910	3,432	3,118	3,191	3,407	3,567	3,680	3,756
3 NJ	1,265	1,384	1,462	1,565	1,562	1,519	1,675	1,707	1,895	1,786
4 DE, PA	1,868	2,027	2,015	2,443	2,248	2,509	2,584	2,601	2,738	2,720
5 MD, DC, VA, WV	2,219	2,299	2,430	2,438	3,051	2,943	3,034	3,159	3,258	3,373
6 NC, SC, GA	2,829	3,096	3,220	3,587	3,396	3,565	3,784	3,903	4,170	4,561
7 FL	2,315	2,534	2,593	2,690	2,937	3,087	3,041	3,183	3,312	3,450
8 AL, MS, TN	1,950	2,035	2,054	2,365	2,290	2,413	2,602	2,634	2,751	2,794
9 IN, KY, OH	2,518	2,817	2,987	2,926	3,536	3,298	3,329	3,619	3,802	4,164
10 IL	1,828	1,915	2,206	2,272	2,172	2,207	2,321	2,490	2,539	2,601
11 MI, MN, ND, SD, WI	2,204	2,466	2,651	2,987	2,826	3,073	3,103	3,361	3,493	3,680
12 IA, KS, MO, NE	1,443	1,547	1,527	1,764	1,642	1,744	1,854	1,982	2,153	2,179
13 AR, LA, OK	1,367	1,524	1,667	1,824	1,847	1,760	2,025	2,069	2,189	2,283
14 TX	2,158	2,444	2,411	2,519	2,530	2,674	2,727	3,000	3,242	3,297
15 AZ, CO, NV, NM, UT, WY	1,156	1,277	1,350	1,462	1,405	1,589	1,633	1,793	1,941	1,930
16 AK, ID, MT, OR, WA	1,015	909	1,036	1,184	1,134	1,198	1,201	1,273	1,402	1,497
17 N. CA, HI	1,565	1,548	1,652	1,789	1,791	1,813	1,899	2,077	2,239	2,361
18 S. CA	2,249	2,333	2,575	2,874	2,851	2,925	2,922	3,359	3,461	3,620
All	33,877	36,465	38,473	42,029	42,180	43,409	45,117	47,841	50,198	52,359

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown network are excluded so that rates can be calculated properly.

Table A.21
Incident Rates of Reported ESRD, by Diabetic Status & ESRD Network
per million population, adjusted for age, gender, & race

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	207	226	222	273	270	274	281	292	260	305
2 NY	191	211	219	257	249	269	285	292	301	303
3 NJ	241	252	263	295	311	303	326	339	358	332
4 DE, PA	229	247	232	294	284	311	319	327	342	342
5 MD, DC, VA, WV	215	229	227	232	278	292	311	317	327	329
6 NC, SC, GA	212	227	230	261	302	329	284	296	304	325
7 FL	222	242	240	246	260	299	280	288	295	308
8 AL, MS, TN	212	227	214	258	264	278	296	300	314	319
9 IN, KY, OH	206	235	238	227	297	298	296	326	342	359
10 IL	234	255	264	290	291	299	306	326	346	345
11 MI, MN, ND, SD, WI	207	230	236	273	268	287	290	309	311	323
12 IA, KS, MO, NE	216	230	237	271	261	289	293	320	334	335
13 AR, LA, OK	212	231	235	261	278	271	311	320	338	338
14 TX	254	276	278	292	297	319	332	362	365	371
15 AZ, CO, NV, NM, UT, WY	216	228	233	244	254	259	266	288	297	298
16 AK, ID, MT, OR, WA	213	206	222	236	226	239	237	253	258	279
17 N. CA, HI	233	229	238	260	262	270	290	305	303	329
18 S. CA	248	247	254	298	303	311	323	361	367	378
All	219	235	239	266	275	289	300	315	325	334
DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	69	79	70	102	104	108	117	123	104	119
2 NY	63	69	68	83	91	106	113	115	120	120
3 NJ	81	80	84	106	124	123	132	144	144	132
4 DE, PA	80	87	75	102	112	120	126	133	138	142
5 MD, DC, VA, WV	68	80	73	81	93	113	129	129	136	136
6 NC, SC, GA	73	78	77	96	116	137	117	127	129	135
7 FL	68	78	73	82	83	111	108	111	114	123
8 AL, MS, TN	68	80	70	91	104	111	122	120	134	136
9 IN, KY, OH	69	83	82	76	112	126	130	145	153	157
10 IL	73	76	74	98	109	116	116	124	142	137
11 MI, MN, ND, SD, WI	80	88	85	100	108	122	125	131	130	133
12 IA, KS, MO, NE	78	86	87	101	111	122	129	142	145	150
13 AR, LA, OK	79	88	83	94	110	117	130	142	150	141
14 TX	106	114	121	132	142	157	171	183	183	191
15 AZ, CO, NV, NM, UT, WY	88	95	98	101	122	117	126	137	142	145
16 AK, ID, MT, OR, WA	80	90	91	87	97	99	108	104	112	118
17 N. CA, HI	83	87	90	105	109	116	132	139	130	146
18 S. CA	99	96	93	119	128	135	152	167	174	181
All	78	85	83	98	109	121	129	137	141	145
NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	138	147	152	171	166	166	164	169	156	186
2 NY	128	142	151	174	158	163	172	177	181	183
3 NJ	160	172	179	189	187	180	194	196	215	200
4 DE, PA	149	160	158	192	172	191	193	193	204	200
5 MD, DC, VA, WV	147	149	153	151	185	178	183	187	192	193
6 NC, SC, GA	139	150	153	165	186	193	168	169	175	190
7 FL	154	164	167	164	177	188	171	177	181	185
8 AL, MS, TN	144	147	144	166	160	167	174	180	180	183
9 IN, KY, OH	137	152	156	151	185	172	166	180	189	202
10 IL	161	179	189	192	182	183	190	202	204	208
11 MI, MN, ND, SD, WI	127	141	151	173	160	165	165	178	181	190
12 IA, KS, MO, NE	138	143	150	170	150	167	164	178	189	185
13 AR, LA, OK	133	143	153	167	168	154	181	178	188	197
14 TX	148	162	157	160	155	161	161	178	182	180
15 AZ, CO, NV, NM, UT, WY	128	133	135	143	132	142	140	151	155	153
16 AK, ID, MT, OR, WA	133	116	131	149	129	140	128	149	146	161
17 N. CA, HI	150	142	148	155	153	153	158	167	173	183
18 S. CA	149	151	162	179	175	175	171	194	193	197
All	142	150	156	168	166	168	171	179	185	189

The incident cohorts and associated modalities are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown network are excluded so that rates can be calculated properly.